Abstract: COVID-19 symptoms, including hypokalemia, hypoalbuminemia, ageusia, neurological dysfunctions, D-dimer production, and multi-organ microthrombosis reach beyond effects attributed to impaired angiotensin-converting enzyme 2 (ACE2) signaling and elevated concentrations of angiotensin II (Ang II). Although both SARS-CoV (Severe Acute Respiratory Syndrome Coronavirus) and SARS-CoV-2 utilize ACE2 for host entry, distinct COVID-19 pathogenesis coincides with the acquisition of a new sequence, which is homologous to the furin cleavage site of the human epithelial Na\(^{+}\) channel (ENaC). This review provides a comprehensive summary of the role of ACE2 in the assembly of Na\(^{+}\)-dependent transporters of glucose, imino and neutral amino acids, as well as the functions of ENaC. Data support an osmotic adaptation mechanism in which osmotic and hemostatic instability induced by Ang II-activated ENaC is counterbalanced by an influx of organic osmolytes and Na\(^{+}\) through the ACE2 complex. We propose a paradigm for the two-site attack of SARS-CoV-2 leading to ENaC hyperactivation and inactivation of the ACE2 complex, which collapses cell osmolality and leads to rupture and/or necrotic death of swollen pulmonary, endothelial, and cardiac cells, thrombosis in infected and non-infected tissues, and aberrant sensory and neurological perception in COVID-19 patients. This dual mechanism employed by SARS-CoV-2 calls for combinatorial treatment strategies to address and prevent severe complications of COVID-19.

Keywords: angiotensin; tonicity; transporters; virus; thrombosis; hypertension; coagulation; organ failure; inflammation

1. Introduction

Viruses have evolved to hijack specific multifunctional proteins that assist in viral entrance and subsequent viral proliferation, while simultaneously disabling the host’s metabolic responses and defense mechanisms. This strategy is employed through Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) and SARS-CoV-2 beta coronaviruses’ binding and utilization of angiotensin-converting enzyme 2 (ACE2) (reviewed in [1]). ACE2 is a type I integral membrane protein expressed in epithelial and vascular endothelial cells in the lungs, intestines, heart, kidneys, brain, and other organs (reviewed in [2]). The classical function of ACE2 is the cleavage of peptide hormone angiotensin II (Ang II) within the renin-angiotensin system (RAS) (Figure 1, reviewed in [3,4]). Ang II binds to Ang II receptor type I (AT1R) to control blood pressure, and multiple other responses [1] in barrier tissues expressing ACE2 (Figure 2A) [2]. The resulting ACE2 cleavage product Ang (1–7) mediates vasodilatory and anti-inflammatory effects through the MAS receptor (alias Mas1, MasR; reviewed in [5,6]) (Figure 2B), which counteracts the damaging effects of Ang II/AT1R (reviewed in [7]).
Surprising findings in mice deficient in ACE2 (Ace2−/−) reveal that ACE2 does not directly control blood pressure [8] and has a gamut of functions that cannot be attributed merely to the cleavage of Ang II [9,10]. Emerging studies suggest that several new functions attributed to ACE2 depend on interactions with other proteins [11–14], which are the focus of this review.

The highly pathogenic SARS-CoV-2 coronavirus, with a lower affinity but higher efficacy of interaction with ACE2 than SARS-CoV [12,15,16], is now a global public health threat exceeding 45 million cases worldwide (updated online [17]). ACE2 catalytic site is an entry route for SARS-CoV-2, which impacts the cleavage of Ang II (Figure 2C) resulting in a shift in an inflammatory response from Ang II [9,10]. Emerging studies suggest that several new functions attributed to ACE2 depend on interactions with other proteins [11–14], which are the focus of this review.

Figure 1. Components of the Renin-Angiotensin System (RAS). Bioactive peptides of angiotensinogen, Ang I or Ang (1–10), Ang II or Ang (1–8), and Ang (1–7) are depicted as rectangular shapes. The cleavage enzymes of renin, angiotensin-converting enzyme (ACE), ACE2, cathepsin A (CatA), and neprilysin are indicated in italics. The central panel shows the canonic RAS pathway. ACE cleaves dipeptide His-Leu, which converts decapeptide Ang I into octapeptide Ang II (blue rectangles). ACE2 cleaves a neutral amino acid, Phe, that converts Ang II into Ang 1–7 (orange rectangles). The alternative pathways by ACE and ACE2 (black arrows) as well as those mediated by other enzymes (gray lines) are shown on the right. Captopril is synthetic and Ang 1–7 and Ang 1–9 are natural inhibitors of ACE (red lines). Ang 1–7 inhibition presents a classical feedback mechanism for physiological control of Ang II levels in circulation. One example of the convergence of Ang II with other endocrine pathways for the regulation of blood pressure is shown on the left. Circulating Ang II initiates the production of aldosterone (Aldo) from cholesterol in the adrenal cortex.

The critical pathophysiological scenarios of severe morbid COVID-19 manifestations (reviewed in [19]), particularly venous microthrombosis, did not occur under severe inflammatory conditions mediated by other viruses [20] and reaches beyond inhibition of the catalytic function of ACE2. In this review, we summarize recent findings regarding an ACE2-centered supramolecular complex and propose the critical role of ACE2 in the regulation of cell volume in the context of coagulation, which becomes apparent after the disrupting impact of SARS-CoV-2 infection. We outline distinct pathways triggered by a unique SARS-CoV-2 structural site [21] responsible for effective viral transmission and severe pathogenicity of COVID-19. The goal of this theoretical paper is to provide a framework that assists researchers across multiple fields in experimentally examining both the functions of ACE2 in network with other proteins, and the malfunction of this network in the presence of SARS-CoV-2.
Figure 2. Schematic regulation of ACE2-dependent pathways under physiological conditions and during SARS-CoV-2 infection. (A) Main signaling in the absence of ACE2 when it is not expressed, or its activity is inhibited (ACE2 is ‘OFF’). Circulating Ang II binds to its high affinity G-protein-coupled receptor AT1R. Main AngII/AT1R signaling mediates vasoconstriction, NADPH oxidase activation and reactive oxygen species (ROS) formation, hypoxia induction (HIF1α), activation of MMPs, including ADAM17 and pro-inflammatory cytokines, Na+/H2O retention from extracellular fluids into blood, hypertension, hypertrophy, activation of sympathetic nerves and other effects. Ang II/AT1R receptor can suppress angiotensin 2 receptor (AT2R, red lines) expression in the initial stages of inflammation, but this suppression is alleviated by interferon regulatory factor 1 (IRF-1). Ang II also activates AT2R, sometimes in complex with different proteins, which opposes the effects of Ang II/AT1R and resolves stress, inflammation, and apoptosis. Under specific conditions, Ang II/AT2R response could mimic Ang II/AT1R possibly by involving further cleavage of Ang II. MAS receptor remains inactivated (OFF) without ligand Ang (1–7), produced from Ang II. (B) The main signaling in the presence of catalytically active ACE2 (ACE2 is ‘ON’). Activated ACE2 is shown as an integral protein with an active catalytic
site containing Zn$^{2+}$ in the ectodomain (green V shape). ACE2 is stabilized in a catalytically active conformation by calmodulin (CaM, red rectangle) bound to an intracellular domain of ACE2 that prevents cleavage of ACE2 by proteases ADAM17 (not shown) or TMPRSS2 (orange line shape). ACE2 cleaves Ang II, leaving both AT1R and AT2R inactive (OFF). ACE2 cleavage produces Ang 1–7, which binds to MAS receptor and elicits signaling that opposes Ang II/AT1R effects and inhibits AT1R expression (red lines). (C) SARS-CoV-2 (circular shape) binds to the catalytic site of ACE2 for entry. SARS-CoV-2 has also acquired a new sequence that mimics the furin cleavage site of human ENaC (blue cylinder inside viral shape). TMPRSS2 is an inhibitor of ENaC; however, in the presence of SARS-CoV-2, it possibly binds to ENaC mimetic site for cleavage of viral spike proteins for replication. Host ENaC remains active (not shown). The resultant pathological response becomes Ang II-centered and cannot be resolved in the absence of Ang (1–7)/MAS signaling due to the functional hindrance of ACE2 by SARS-CoV-2 over a supraphysiological period of time (locked in ‘OFF’). These pathways initiate the pathologies seen in COVID-19 patients (discussed below). Additional inflammatory events triggered by viral mRNA, viral protein and its complexes with host antibodies, host’s inflammatory responses, and probable bacterial co-infections and their lipopolysaccharide (LPS) will be mediated by other receptors (gray dashed square). Although important, these responses will be secondary to viral binding to ACE2 and will not be discussed in this review.

2. ACE2 Structure and Catalytic Site

ACE2 (805 amino acids (aa), 92.5 kD [22,23]) has three principal domains: (1) N-terminal extracellular domain or ectodomain, (2) membrane-spanning domain, and (3) C-terminal intracellular domain. Ectodomain regions that have structural and functional similarity to other molecules are commonly termed ‘domains’, e.g., collectrin-like domain. Each of these functional ‘domains’ or sites have a specific or opportunistic partner that alters its function in conjunction with their physiological and pathological functions, as well as in the context of SARS-CoV-2.

The most characterized extracellular site of ACE2 is a single, conserved zinc metallloprotease consensus HEXXH that efficiently cleaves a neutral aa from the C-terminal of Ang II (alias Ang 1–8) to produce Ang 1–7 and phenylalanine [22]. ACE2 also cleaves other substrates [24] (Box 1). ACE2 cleavage of Ang I provides an alternative cleavage mechanism in animals treated with ACE inhibitors [23] and is relevant for hypertensive patients treated with these compounds. Apelin–13 and dynorphin A are additional high-affinity substrates for ACE2, which exhibit 91% and 60% less activity compared to Ang II (100%), respectively [24]. Catalytically active ACE2 (~120 kD) is glycosylated [22]; however, the requirement of glycosylation for this activity has yet to be examined. Enzymatic activity of ACE2 is not restricted to cells expressing ACE2, since the catalytic ectodomain of ACE2 can be released into circulation following cleavage by proteases ADAM17 and TMPRSS2 [25]. Enzymatic function of ACE2 assures the balance between Ang II and Ang 1–7 [22] within RAS (Figure 1) and apelin pathways [24].

**Box 1.** Characteristics of ACE2 catalysis.

- **Catalytic site:** HEXXH (Alias: HEMGH, or benzylsuccinate insensitive carboxypeptidase, peptidase domain [22]).
- **Low affinity substrates** [23,24]: angiotensin I (Ang 1–10), des-Arg bradykinin, β-casomorphin, ghrelin, neurotensin1–13, neurotensin1–8 kinetensin.
- **Optimal catalytic conditions** [24]: Zn$^{2+}$, pH 6–8; chloride anion (1 M NaCl) binds to Arg514.
- **Inhibitors:** EDTA [23].

3. Effects of Ang II and Its Downstream Target ENaC on Osmosis, Hypertension, and Swelling

Ang II/AT1R is one of the major mechanisms controlling water and Na$^{+}$ concentrations in blood, which contributes to increase in extracellular fluid volume, leading to hypertension (Figure 3) (reviewed and proposed in [26]). Under additional stress, in coordination with hormones (Box 2) Ang II regulates reabsorption of water and Na$^{+}$ in the kidney epithelium. In contrast, lung and vascular tissues have
an autonomous regulation of Na\(^+\) reabsorption from extracellular spaces into epithelium by cellular proteases, including TMPRSS2 and furin (reviewed in [27]).

**Box 2. Ang II/AT1R-regulated hormones.**

- Aldosterone in the kidney cortex [28]; stressor: high salt.
- Vasopressin (or arginine vasopressin) in the hypothalamus [29]; stressor: water deprivation.

Direct targets of Ang II/AT1R on Na\(^+\) reabsorption [30,31] were identified in the Ang II infusion model of hypertension [28]. Although multiple other transporters and claudins contribute to this process, systematic studies in male and female rodents [28,31] revealed a central contribution of an amiloride-sensitive epithelial Na\(^+\) transporter (ENaC) in Na\(^+\) reabsorption from urine and other extracellular fluids [28,31] (Figure 3). Genetic deficiency in \(\alpha\)ENaC, \(\beta\)ENaC, or \(\gamma\)ENaC in the lung results in a morbid electrolyte imbalance leading to lung inflammation and death (excellently reviewed in [32]).

![Figure 3. The principal components of osmotic regulation by Ang II (ACE2 OFF). In the cholesterol-rich membrane (yellow structures) of barrier cells (specified below), Ang II/AT1R activates classical and novel protein kinase C (PKC) and mobilizes Ca\(^{2+}\) from internal stores. Ca\(^{2+}\) binds to calmodulin (CaM), resulting in disassembly of AQP2 and CaM complex retaining AQP2 in the cytosol of cells expressing AQP2 (cortical and medullary renal collecting ducts, pancreatic islets, fallopian tubes, peripheral nerves [33], as well as lymphatic endothelium [34]). PKC phosphorylation of AQP2 (P-AQP2) and Ca\(^{2+}\)-activated cytoskeleton translocate to membrane P-AQP2 for stimulated water influx. Epithelial or](image-url)
endothelial cells express AQP1 and AQP5 (reviewed in [35]). PKC [36] can activate AQP1, whereas a transient receptor potential vanilloid 4 (TRPV4)-triggered [37] mechanism has been proposed for AQP5-mediated water flux reducing lung edema, potentially via PKC activation [38]. Ang II/AT1R mobilizes ENaC for Na\(^+\) influx and its transit through the cell with the help of Na\(^+\)/K\(^+\) ATPase (detailed in Figure 4). Ang II/AT1R inhibits insulin secretion and maintains GLUT4 in the cytosol, which creates a deficit of organic osmolytes in the cell. Glucose influx is mediated via the GLUT1 transporter for glycolytic energy production under Ang II/AT1R-stimulated hypoxia via HIF1\(\alpha\) transcription factor. The deficit of organic osmolytes and Na\(^+\), and an excess of water inflow, leads to cell swelling. Changed cellular tonicity activates NFAT5 transcription factor and its target genes vWF and AQP1; vWF, which stimulate perpetuate microthrombi formation followed by the breaking down of fibrin into D-dimer.

In the adrenal gland, Ang II/AT1R induces aldosterone secretion, which activates ENaC-dependent reabsorption of Na\(^+\) into blood in exchange for K\(^+\) in the kidney. NHE3 reabsorbs Na\(^+\) from urine in exchange for H\(^+\). These transporters establish hypernatremia and hypokalemia in the blood. Hypoalbuminemia in blood compensates for cellular hypotonicity. Ang II/AT1R also stimulates arginin vasopressin (AVP), increasing stimulated thirst, while MAS remains inactivated. Ang II-centric events lead to hypertension treated with ACE inhibitors and AT1R blockers.

In tissues expressing ENaC (described in Box 3), ENaC functions for ~20 min [27] and requires Ang II for its expression and mobilization to the apical membranes [30,31] (Figure 4). Following uptake by ENaC, Na\(^+\) follows an electrochemical gradient to the basolateral membrane, where Na\(^+\)/K\(^+\) ATPase transporters mediate the efflux of Na\(^+\) to the blood in exchange for K\(^+\) [39] (Figure 4). This action establishes a positive transcellular current ~2.7 ± 0.5 \(\mu\)A/cm\(^2\) from apical-to-basolateral sides, known as cell polarization [39]. The electrochemical gradient favors apical cellular K\(^+\) efflux through K\(^+\) channels and the apical H\(^+\)/K\(^+\) pump [39]. These effects establish urinary K\(^+\) excretion in the kidney, leading to a decrease of K\(^+\) and an increase of Na\(^+\) concentrations in the blood [27]. In the lungs, ENaC in conjunction with other transporters establishes a 5-fold greater K\(^+\) concentration in the extracellular airway surface liquid compared to basolateral K\(^+\) concentrations [39] (Figure 4).

**Box 3.** ENaC composition and expression.

| Expression of subunits: \(\alpha\), \(\beta\), \(\gamma\), and \(\delta\): \(\alpha\beta\gamma\)ENaC in kidney, lungs, GI tract, testes, salivary duct [40], vascular endothelial cells [41], other barrier cells \(\delta\)ENaC subunit in neurons, heart, and pancreas. | }

Physiological ENaC activity is regulated by a feedback mechanism dependent on K\(^+\) concentrations (Figure 4). A K\(^+\)-stabilized secondary guanine quadruplex element (G-quadruplex) of DNA [42] is found in promoters of genes involved in the inflammatory response, including proliferative c-Myc [43], anti-apoptotic BCL1, angiogenic VEGF, TMPRSS2 [44] and others (reviewed in [45]). Decreases in intracellular K\(^+\) concentrations alleviate the silencing of the TMPRSS2 promoters and increase gene expression [44] (Figure 4). TMPRSS2 binding to ENaC inhibits ENaC [46], which prevents loss of K\(^+\). TMPRSS2 is a type II transmembrane serine protease [47] that also cleaves ACE2 [25]; however, it is unknown if either the misfolded or oxidized form of ACE2 is the preferred substrate for TMPRSS2. Physiological Ang II concentrations and TMPRSS2 feedback adjust ENaC levels and its activity with functions of other transporters for an ionic osmotic balance between extracellular and intracellular fluids in the kidneys, lungs, and GI tract.
Biomedicines 2020, 8, x FOR PEER REVIEW 6 of 29

In tissues expressing ENaC (described in Box 3), ENaC functions for ~20 min [27] and requires

Box 3.

Figure 4. Pathophysiologic regulation of ENaC in barrier cells, such as type II pneumocytes expressing
ACE2, TMPRSS2 [48], and ENaC [49]. These cells are a validated target of SARS-CoV-2 and exhibit viral
particles in all investigated post-mortem lung tissues of COVID-19 patients [50], though other barrier
cells, including ileal absorptive enterocytes, ciliated cells, and nasal goblet secretory cells, can also be
infected [48]. Endothelial cells express ACE2, but not TMPRSS2 in the post-mortem lung tissues from
COVID-19 patients [51]. Endothelial cells do not contain SARS-CoV-2 particles [50] but exhibit osmotic
malfunctions: swelling, rupture, microthrombosis, and/or necrosis in these tissues [20,50], that may
involve ENaC expressed in these cells [41]. Physiologic regulation of ENaC activity is facilitated via
feedback mechanism. In the ‘OFF’ state of ACE2, Ang II/AT1R (green arrow) induces mobilization
and expression of the αβγENaC (blue, yellow, and orange shapes) to the apical side of barrier cells.
Na⁺ follows a gradient to the basolateral side where Na⁺/K⁺ ATPase transporters mediate efflux of
Na⁺ into the blood in exchange for K⁺. Na⁺/K⁺ ATPase transporters, cystic fibrosis transmembrane
conductance regulator (CFTR), and Na⁺-K⁺-Cl⁻ cotransporter 1 (NKCC1) are expressed in pneumocytes
and regulate alveolar fluid balance [52]. This Na⁺ flow establishes a positive transcellular current
(polarization) of ~2.7 ± 0.5 μA/cm². The K⁺ follows a gradient to the apical side where its efflux is
mediated by multiple transporters leading to a 3–5-fold higher concentration of K⁺ in airway surface
fluid (15–27 mM K⁺), compared to blood (5 mM K⁺). TMPRSS2 (orange line shape) binding inhibits
ENaC; however, TMPRSS2 is suppressed by K⁺ ions bound to G quadruplex in the promoter region
(nucleus). Intracellular loss of K⁺ activates TMPRSS2 expression creating a potential feedback loop
for inhibition of ENaC activity. Pathologic regulation. The furin cleavage site on SARS-CoV-2 is
homologous to human ENaC and therefore, can provide an alternative site for binding of TMPRSS2,
which can cleave SARS-CoV-2 for replication. Host’s ENaC remains activated without inhibition
by TMPRSS2.
The progressive urinary loss of K cannot be compensated by recruitment of other transporters, NCC [53], Kir4.1, Na+/H+ exchanger (NHE3) [28], or AT2R in nephrons [54], which leads to severe hypertension [28,30]. Overactivation of ENaC is lethal. In genetic studies, overexpression of prosatin, activating ENaC, leads to electrolyte imbalance and hypertension in mice [55]. Overactivation of ENaC in the lung epithelium in mice deficient in ubiquitin ligase Nedd4L (Nedd4L−/−) also results in lung inflammation, fibrosis, and death, which could be rescued by administration of nasal amiloride inhibitor of ENaC [56]. Although Nedd4L has different targets (reviewed in [57]), the experiment with amiloride highlights the chief role of ENaC in lung inflammation. In humans, a genetic overactivation mutation in βγENaC [58] causes Liddle syndrome. In this disease, excessive reabsorption of Na+ by overactive βγENaC leads to expanded extracellular fluid volume that suppresses renin and aldosterone causing severe hypertension in childhood accompanied by hypokalemia and high pH (metabolic alkalosis) [27]. TMPRSS2 inhibition of ENaC [46] provides a fine-tuning of electrolytes and osmolytes, and protects from hypokalemia.

Overproduction of Ang II, aldosterone, vasopressin, and/or inflammatory cytokines (reviewed in [59]) compromises intracellular osmotic stability [60] by diminishing the supply of organic osmolytes, particularly glucose. Ang II reduces secretion of insulin, and glucose uptake by GLUT4 and SGLT1 [61] (Figure 3). Instead, Ang II upregulates GLUT1, transporting glucose to meet energy demands. The loss of intracellular Na+ and organic osmolytes in the cell does not necessarily alter the concentration of these metabolites in circulation. Albumin compensates for reduced intracellular concentrations of ions and organic osmolytes in order to achieve Donnan equilibrium [62]. The reduction of 1 g/dL albumin in serum (reviewed in [63,64]) corresponds to a reduction of 2 mmol Na+/L [62]. Ang II-mediated stress [65] is accompanied by hypoalbuminemia, which is a diagnostic marker for intracellular hyponatremia [66].

Ang II stress is exacerbated by changes in water homeostasis. Ang II/AT1R engages Gαq/11, which in turn activates phospholipase C (PLC) [67] leading to Ca2+ release (reviewed in [68]) and activation of conventional and novel PKC types [68] (Figure 3). PKC-mediated phosphorylation of aquaporins AQP1 [69] and AQP5 [70] leads to their translocation to the membrane surface for stimulated water influx overriding tonicity and concentration of organic osmolytes [69]. In the kidney, Ang II/AT1R induces a similar PKC signaling cascade, including calmodulin (CaM) and PKC activation, which increases AQP2-dependent water reabsorption from urine into the blood [71]. Ang II-dependent release of arginine vasopressin stimulates thirst and additional water reabsorption in the kidney by AQP2 [71] (Figure 3). Arginine vasopressin overrides the physiologic regulation of tonicity in cardiac muscles under chronic heart failure conditions by stimulation of water influx through AQP2 in the renal collecting duct [72], which induces hyponatremia [73]. Ang II/AT1R in the central nervous system (CNS) appears to govern cardiac effects, hence overexpression of human ACE2 in mouse neurons was sufficient to prevent cardiac tissue remodeling and associated blood pressure for at least 14 days [74]. Cumulatively, the deranged osmotic balance and water influx often contribute to cellular hypertrophy and swelling in the presence of Ang II [74].

The regulation of extracellular osmotic responses was validated in the loss-of-function AT1R−/− [29] and Ace−/− mice with reduced Ang II production. In these mice, deficient Ang II/AT1R signaling reduced blood pressure by decreasing urine osmolality (−64%) and increasing urinary water content [29]. Given these established functions of Ang II, the gain of Ang II function in Ace2−/− mouse model was created [8] and was expected to highlight blood pressure regulation by Ang II. However, the phenotype of Ace2−/− mice revealed that ACE2 function in osmotic balance reaches beyond the traditional cleavage of Ang II.

4. ACE2 Partnership with Neutral aa Transporter B0AT1

The identification of an integral role of ACE2 in the assembly of a multiprotein complex [75] marks the beginning of the quest for additional functions of this protein. ACE2 is an obligatory partner of Na+-dependent B degrees-like neutral aa transporter (B0AT1, gene Slc6a19) in the intestine, where
Ace2 deficiency abolishes expression of Slc6a19 [10]. B⁰AT1 transports neutral aa (Box 4) and Na⁺, leading to membrane depolarization [11].

**Box 4.** Neutral aa (monoamino monocarboxylic aa).

| Alanine, asparagine, citrulline, glutamine, histidine, isoleucine, leucine, phenylalanine, serine, threonine, tyrosine, tryptophan, and valine. |

Its partnership with either collectrin (Alias TMEM27, gene Slc6a18) or ACE2 in most tissues is required to elicit a 10-fold higher activity of B⁰AT1 [10] due to enhanced mobilization and expression of this protein. A complex is formed between ACE2's collectrin-like domain and B⁰AT1 [12]; then, two of these heterodimers form a dimer [12] (Figure 5A). Disruption of this complex in Ace2⁻/⁻ mice severely impairs absorption of dietary neutral aa, muscle composition weight, growth, and development on a regular diet, and these abnormalities are exacerbated on low-protein diets [9].

![Figure 5. Cumulative function of ACE2 complex with Na⁺-dependent transporters. (A) Schematic presentation of enzymatically active ACE2 homodimer undergoing heterodimerization with sodium-dependent transporter B⁰AT1 (SLCA19) to stabilize this complex, based on cryo-electron microscopy.](image-url)
structure [12]. ACE2 homodimerization is mediated by polar interactions and disulfide bridge formation. ACE2 is stabilized by CaM to avoid shedding. B^0AT1 interacts with extended collectrin-like domain of ACE2. B^0AT1 transports neutral amino acids (nAA including Phe cleaved from Ang II) across the apical membranes of small intestine, lungs and other organs, excluding the kidneys. One Na^+ is co-transported per amino acid. (B) ACE2 complex with Na^+-dependent transporters contribute to regulation of physiological cell volume and normotension in blood. For clarity, here and below, the ACE2 dimer has been shown as a monomer. ACE2/B^0AT1 complex also includes other Na^+-dependent transporters, such as SIT for imino acids (iAA) and Cl^- and SGLT1 for glucose (Glu). In addition to their metabolic value, these nAA, iAA, and glucose serve as organic osmolytes, which maintain osmolality together with Na^+ ions. Water influx is mediated by aquaporins (AQ1P1 and AQ1P5) in response to hypotonicity. Insulin secretion is controlled by pancreatic activity of ACE2/B^0AT1 complex that increase glucose intake by glucose transporter 4 (GLUT4). The balanced levels of organic osmolytes, ions, and water sustain physiologic cell volume, thereby NIfAT5 and its target genes vWF and AQ1P1 remain inactive (OFF). In the kidney, B^0AT1 functions in a complex with collectrin, where it reabsorbs nAA and Na^+ from urine. Ang (1–7)/MAS signaling in the brain regulates adaptive osmotic thirst [76]. Unliganded AT1R receptor is inactive. The concentration of water, albumin, K^+ , and H^+ is in the physiologic range. Physiological cell volume is accompanied by normotension on blood when ACE2 complex is intact.

Collectrin is an obligatory partner of B^0AT1 only in the kidney [77], where deficiency in collectrin manifests with severe neutral hyperaminoaciduria [77]. Loss-of-function mutations of B^0AT1 [78] can cause one or multiple symptoms of the autosomal recessive Hartnup disorder (OMIM 234500) [78,79], particularly aminoaciduria, stunted growth, and development [75]. In this disease, the deficient transport of tryptophan for the synthesis of niacin can manifest as dermatitis and/or cerebellar ataxia [78,79] resembling pellagra. Notably, these symptoms also develop in patients with mutations (e.g., R240Q) [10,11,78], which spare the transport function of B^0AT1, but, however, disable the formation of the ACE2/B^0AT1 complex [11,12]. Thus, the interaction between B^0AT1 and ACE2 is critical for functional competence of both molecules.

The uptake of dietary and cleaved neutral aa together with Na^+ by B^0AT1 (Figure 5A) provides both nutrients and organic osmolytes that regulate physiological cell volume [60]. Data support clustering of ACE2/B^0AT1 with two other osmolyte transporters [75,80] (Figure 5B). (1) Na^+ and Cl^-dependent imino acid transporter SIT1 (gene Slc6A20) interacts with ACE2 and B^0AT1 [75] in human and murine intestine [80]. Genetic deficiency of SIT1 leads to iminoaciduria, stunted growth, and development [75]. In this disease, the deficient transport of tryptophan for the synthesis of niacin can manifest as dermatitis and/or cerebellar ataxia [78,79] resembling pellagra. Notably, these symptoms also develop in patients with mutations (e.g., R240Q) [10,11,78], which spare the transport function of B^0AT1, but, however, disable the formation of the ACE2/B^0AT1 complex [11,12]. Thus, the interaction between B^0AT1 and ACE2 is critical for functional competence of both molecules.

5. Evidence of ACE2-Dependent Regulation of Osmolality, Cell Volume, and Susceptibility to Thrombosis

The phenotype of Ace2^−/− mice provides evidence of the role of ACE2’s regulating intracellular osmolality. Ace2^−/− mice lack Ang II cleavage [8] and are also deprived of other anti-hypertensive peptides, such as Ang (1–7) [85,86] and Ang (1–9) [87] (Figure 3). Nonetheless, despite high Ang II levels [8], Ace2^−/− mice have normal blood pressure [8]. This finding appears paradoxical, if other phenotypic manifestations in Ace2^−/− mice described in the fundamental work by Verrey and
coworkers [9], are not considered. Osmotic adaptation was severely compromised in these mice and was dependent on protein content in the diet. Ace2−/− mice retained significantly higher content of water in tissues (147%) vs. WT (100%) on a diet with normal protein content [9], in agreement with Ang II-stimulated water retention by Ang II. On a low-protein diet, the water content was decreased in WT (89%); however, it continued to increase in Ace2−/− mice (213%), suggesting that the levels of organic osmolytes were dependent on ACE2 and likely on its interaction with B0AT1 and SIT1. The deregulation in organic osmolyte levels was pronounced in urine. Osmolality was decreased to 56% in urine of Ace2−/− mice vs. WT (100%) on a normal protein diet. A low-protein diet reduced osmolality to 40.5% in WT mice and to 16% in Ace2−/− mice compared to the osmolality in WT mice fed a diet with normal protein content [9]. These changes in urinary osmolality may depend on reduced intestinal absorption of neutral aa in Ace2−/− mice with a dysfunctional ACE2/B0AT1/SIT1/SGLT1 cluster [9].

The osmotic deregulation in tissues of Ace2−/− mice is blunted, due to the partial compensation by the collectrin/B0AT1 complex [10], particularly in the kidney [75] (Figure 3). A full view on the regulation of intracellular osmolyte concentrations could be obtained in tissue-specific knockout models lacking both Ace2 and collectrin. Cardiac tissues naturally express low levels of collectrin [88], and manifest with early deregulation of myocyte size and cardiac hypertrophy in Ace2−/− mice [89]. The distinct osmotic mechanism in cardiomyocytes is supported by incomplete inhibition of this process by AT1R blocker olmesartan [89], or Ang (1–7)/MAS [90], thus, arguing against mechanisms related to enzymatic cleavage of Ang II. The Ang II-independent effect on hypertrophy was also corroborated by findings in mice with cardiac-specific expression of ACE [91]. Ang II production in the hearts of these mice did not increase cardiac hypertrophy over the effects seen in WT after aortic binding [91]. The expended volume of Ace2−/− cardiomyocytes was not compensated by other conventional mechanisms, including an act of active volume regulation [92], as well as transport system A [60] or amino acid antiporter SLC1A5 (ASCT2) [93]. In agreement with the osmotic mechanism, dysfunctional transport of aa by B0AT1 [82], stunting mTORC1 activation [94], provokes cardiac hypertrophy. The interaction of ACE2 with B0AT1 might also be at work for regulation of osmolality in humans, given a rare SLC6A19-MS7 minisatellite polymorphism associated with essential hypertension [95]. Collectively, these data appear to support a requirement of both ACE2, B0AT, and probably, SIT1/SGLT1 for signaling and adaptive regulation of osmolality and cell size (Figure 5B).

Depletion of intracellular aa activates tonicity-regulated transcription factor NFAT5 (or nuclear factor of activated T cells Alias: TonEBP) [96], triggering production of von Willebrand factor (vWF) [97], AQP1 [98] and cyclooxygenase 2 (COX2) [98] in vascular endothelial cells [97] (Figure 3). Disbalance between extracellular and intracellular glucose concentrations can also upregulate NFAT5 [98]. This osmotic instability-mediated release of vWF perpetuates microthrombosis, which is followed by thrombolysis increasing D-dimer concentrations in the blood [97]. The osmotic instability precedes vascular thrombosis in capillaries triggered by an additional stressor. Unlike local inflammation-induced arterial thrombosis, osmotic thrombosis affects multiple endothelial cells with deranged intracellular tonicity and can occur simultaneously in multiple capillaries of several organs. ACE inhibitors and AT1R blockers are not efficient in prevention of venous thrombosis dependent on Ang II. The correction of impaired intracellular tonicity provoking high circulating D-dimer levels with organic osmolytes (Figure 5B) may provide a protective strategy against progression of this unstable state to microthrombosis.

6. Disruptive Viral Partners ACE2 Catalysis

Coronaviruses SARS-CoV, HCoV-NL63, and SARS-CoV-2 have evolved as disruptive opportunistic binding partners of ACE2 [99–101]. SARS-CoV and SARS-CoV-2 share 80% amino acid sequence identity [101] and use a principally similar mechanism for cell entry that requires both ACE2 [101] and TMPRSS2 [102] (Figure 2C, Box 5). The S1 subunit in the viral envelop spike S1/S2 protein interacts with the catalytic site of ACE2 [101] via a viral receptor binding domain [102]. TMPRSS2-mediated cleavage at the S1/S2 and the S2’ sites is indispensable for infectivity in most cells; except for human
lung cancer Calu-3 cells [102] that utilize endosomal cysteine proteases cathepsins B/L (Cat B/L) [103] or proprotease furin [104]. Both viruses attack by binding to the catalytic domain of ACE2 with similar affinity [12,105]. SARS-CoV-2 has a larger interface for interaction with the human ACE2 [12,105] than SARS-CoV; however, SARS-CoV-2 acquired a new furin cleavage site sequence that underlies its distinct pathogenicity and infectivity in the context of interaction with TMPRSS2 (discussed next).

Box 5. Components of SARS-CoV-2 invasion mechanisms.

**New structural sequence on SARS-CoV-2:** Furin cleavage site [104,106] homologous to human ENaC furin cleavage site [21].

**SARS-CoV-2 binding for entry:** SARS-CoV-2 binds to catalytic side of ACE2 or ACE2 complex with B0AT1 [12].

**SARS-CoV-2 cleavage:**
- Extracellular: Host’s principal protease TMPRSS2 cleaves S1-S2 proteins of SARS-CoV-2 [102,104,106]. Relevant physiological functions of TMPRSS2: (1) ACE2 cleavage and inactivation [25], (2) ENaC inhibitor [46].
- Intracellular proteases: Furin [104,106,107]. Relevant physiological functions of furin: (1) ENaC cleavage and activation [108].
- Alternative proteases: Cathepsins B/L (Cat B/L) [103].

**Principal SARS-CoV-2-infected cells types:** pneumocytes type II [50] (Express ACE2, TMPRSS2, furin, ENaC [48,49].

**Additional SARS-CoV-2-infected cells types:** macrophages [50], as well as enterocytes, ciliated cells, and nasal goblet secretory cells [48].

The most revealing aspect of a recent cryo-electron microscopy in vitro study [12] is that a stable SARS-CoV-2 interaction is achieved by binding to either ACE2 homodimer or an ACE2 dimer of heterodimers in complex with B0AT1 (Figure 5A). The dimerization of the cytosolic domain of ACE2 exists in open and closed ‘claw-like’ conformations [12]. SARS-CoV-2 can bind only to the closed conformation. This study implies that SARS-CoV-2 may only have a narrow window of opportunity to bind to an ACE2, in a specific redox state and conformation, and only in the absence of Ang II or apelin substrates. It is unclear how dimeric and/or monomeric forms of ACE2 influence the activity of B0AT1 and SIT1/SGLT1 in response to the binding of one or two SARS-CoV-2 particles in patients with COVID-19. Elevated levels of Ang II are reported in COVID-19 patients and are directly proportional to viral load [109]. In agreement with the Ang II/ATR1 responses, these patients exhibit high levels of circulating inflammatory markers, such as C-reactive protein (CRP) [109], hence SARS-CoV-2 binding to ACE2 results in the prolonged, ‘locked’ state governed by high levels of Ang II (Figure 2C). The mortality was higher in patients using ACE inhibitors and AT1R blockers (36.8%) than in patients without their use (25.6%) [110], suggesting that at this stage of pathogenesis, Ang II may compete with SARS-CoV-2 for binding to ACE2, thereby decreasing viral load. However, a larger study [111] found similar mortality in patients with or without ACE inhibitors/AT1R blockers. Proapelin and apelin levels were not investigated in COVID-19 patients, and their contribution to lung inflammation and injury remains unknown. We will extrapolate the contribution of ACE2 complex to pathogenesis based primarily on the clinical data reported in COVID-19 trials and mechanistic studies in the model systems.

SARS-CoV-2 appears to disrupt the assembly of the B0AT1/SIT1/SGLT1 complex with ACE2 for the absorption of aa and glucose. In one third of transgenic mice expressing human ACE2 [112], 30% t-hACE2 mice lost 20% of initial weight within 2–6 days after SARS-CoV-2 infection [112]. COVID-19 patients, both lean and obese, also rapidly lose −36.9% and −24.4 % fat mass, respectively, accompanied by wasting of lean mass during their 20 days of hospitalization [113]. Although inflammation and hospitalization stress are canonic contributors to wasting syndrome considered in this study [113], malabsorption of glucose and amino acids by B0AT1/ SIT1/SGLT1 complex in the presence of SARS-CoV-2 could underlie wasting. Diarrhea, vomiting [114], anosmia, ageusia and dysphagia [115] could augment weight loss in patients with SARS-CoV-2 infection. Neutral aa
may alleviate these symptoms. ACE inhibitors improve the expression of both Ace2 and Slc6A19, as well as other amino acid Slc36A1 and Slc15A1 transporters in the intestinal tissues in treated vs. untreated patients [80]. Whether ACE inhibitors provide a therapeutic remedy for rapid weight loss in COVID-19 patients remains to be determined. Other pro/con considerations of ACE and ATR1 inhibitors were recently discussed [116]. Hijacking of the ACE2 complex is a key feature shared by pathogenic SARS-CoV, HCoV-NL63, and SARS-CoV-2; however, severe pathogenicity and infectivity coincide with the acquisition of new structural sequences by SARS-CoV-2 [21] and the ability to facilitate interaction with TMPRSS2 [117].

6.1. Structural Site of SARS-CoV-2 and Hyperactivation of ENaC

A notable difference in SARS-CoV and SARS-CoV-2 is a multibasic sequence that is homologous to the furin cleavage site on the αENaC ectodomain [21]. This near-identical furin site enhances SARS-CoV-2 cleavage for replication [104,106] and implies competition between it and the hosts’ αENaC in endosomes for furin-mediated cleavage. Furin is a physiological activator of ENaC [108]. In the absence of furin, ENaC is cleaved on different sites [118,119] by extracellular proteases, including channel-activating protease (CAP1) [120], CAP2/TMPRSS4, CAP3/matriptase, and plasmin [119] (reviewed in [55]), resulting in overactive ENaC. Under inflammatory conditions, this pathway can resolve edema in a mouse model of acute respiratory distress syndrome (ARDS) [119]. ENaC overactivation is promoted by Ang II and leads to loss of K⁺ and an increase in TMPRSS2 expression, which inhibits ENaC (Figure 4, physiological scenario). SARS-CoV-2 employs both furin and TMPRSS2 proteases for its S1/S2 cleavage and subsequent fusion with the host membrane [104,106]. The SARS-CoV-2 sequence mimicking αENaC [21] can potentially bind TMPRSS2, thereby, alleviating inhibition of αENaC by TMPRSS2 [46] (Figure 4, pathological scenario). This arrangement will lock ENaC in acute respiratory distress syndrome a hyperactivation state, ensuring TMPRSS2 expression and redirection of its function for SARS-CoV-2 cleavage. Together, these events can multiply the efficacy of SARS-CoV-2 invasion and cause severe damage to host tissues by hyperactive ENaC.

6.2. Evidence of Osmotic Crisis in COVID-19

Transport of Na⁺ by ENaC [46] determines the volume of airway surface fluid in lungs and K⁺ concentration in blood (Figure 4) (excellently reviewed in [32]). The replication of SARS-CoV-2 in 85% of severely ill patients was associated with profound <3–3.5 mmol/L hypokalemia [121], which was confirmed using a weighted mean difference from five pooled studies [122]. The levels of K⁺ were proportional to the severity of disease measured by body temperature, CRP, and other factors [121]. Hypokalemia occurs despite supplementation with K⁺ [121] and was accompanied by hyponatremia and hypocalcemia: only Cl⁻ levels were within physiological range [122]. The hypoalbuminemia in COVID-19 patients [121] suggests a change in Donnan equilibrium, due to imbalance in the intracellular organic osmolytes and Na⁺. Although mechanistic studies would provide analysis of these phenomena in the future, these clinical findings are consistent with hyperactivation of ENaC. In fact, lung weight among patients who died from influenza A-induced ARDS was 230% heavier than lung weight in COVID-19 patients (161%), compared to the lung weight in age-matched control group patients without ARDS (100%) [20]. In influenza A-infected cells, inflammatory cytokines induce vascular permeability and extracellular efflux of Na⁺ and water [59]. In contrast, hyperactive ENaC, which mediates influx Na⁺ and water into lung epithelium, is a probable factor accounting for differences in fluid volume in these lungs.

In lung alveolar cells, organic osmolytes resolve osmotic instability. SGLT1 is expressed in lungs, where it reabsorbs Na⁺ and glucose from the airway surface liquid [123], probably in conjunction with the ACE2 complex (Figure 5B). This function is disrupted in diabetes, and increases the predisposition of patients with diabetes to bacterial infections. Patients with type 2 diabetes infected with SARS-CoV-2 appear to rapidly develop ketoacidosis on standard anti-diabetic medication [124], suggesting impaired influx and deficient intracellular concentrations of glucose. These findings are in agreement with
dysfunction of the ACE2/B0AT1/SIT1/SGLT1 complex in the lungs of patients with COVID-19 [123,125]. The characteristics of permanent unresolved osmotic stress in cells include initiation of reversible thrombosis increasing D-dimer levels in blood, necrosis in ATP-deprived cells, or cell rupture causing acute thrombosis and inflammation. In patients with SARS-CoV-2 infection, increase in D-dimer levels (>2 µg/mL) at hospital admission accurately (92% sensitivity and 83% specificity) predicted mortality from thrombotic events [126]. D-dimer increase is validated in many COVID-19 patients worldwide [127, 128]. Although, viral particles were found primarily (90%) in pneumocytes [50], while endothelial cells expressing ACE2 have no viral particles (0%) [50]. Nonetheless, microthrombosis affects capillaries in multiple organs leading to thrombotic microangiopathy [129] and deep vein thrombosis [130] in COVID-19 patients. These findings support that systemic factors, such as change in cellular osmolality, is implicated in thrombotic events. Arguably [19], venous multiorgan microthrombosis is the most distinguishing characteristic of COVID-19 compared to other viral pathologies.

Necrosis in type 2 pneumocytes occurred in all studied COVID-19 patients [50]. Finally, cell rupture was evident from histological examinations of pulmonary capillaries [20] as well as the elevated marker of cell damage LDH, which affected 60% of COVID-19 patients. Myocardial damage also developed in 7–17% of COVID-19 patients and its progression to myocarditis is responsible for 7% of deaths (reviewed in [131]). The levels of troponin, a marker of myocardial cell damage, correlated with the severity of COVID-19, and mortality levels [110]. These manifestations are consistent with prolonged loss of osmotic balance, but distinct from other viral infections leading to apoptosis induced by inflammation and ROS. Striking differences in ADRS pathogenesis [20] were revealed after direct comparison of histologic analysis of pulmonary vessels from seven patients who succumbed to SARS-CoV-2 or influenza A (H1N1) infections. ACE2 expression was markedly ~10-times reduced in both alveolar and capillary endothelial cells in COVID-19 compared to influenza patients. Microthrombosis was 9-times more prevalent in SARS-CoV-2 than in influenza A(H1N1) pulmonary capillaries [20]. The expression of inflammatory factors IL6, CXCL10, TNFRSF1A, VCAM1 as well as hypoxia transcription factor HIF1A and HMOX1, and IGF1 were similar in both patient groups [20], suggesting specific prothrombotic mechanisms. Combined findings highlight that osmotic crisis involving overactivation of ENaC and suppression of the ACE2 complex can be a critical mechanism of thrombosis.

6.3. Osmotic Instability as a Risk Factor for Severe COVID-19 Pathogenesis

A perplexing feature of COVID-19 is the severity of pathogenesis in different patients ranging from asymptomatic to ARDS augmented by thrombosis and multiorgan failure [132,133]. SARS-CoV infections had similar, although less pronounced manifestations [134]. SARS-CoV-2 pathogenesis is more severe in persons of older age, male sex, and with hypertension, diabetes, obesity, and cardiovascular disease (reviewed in [19]). These metabolic conditions are linked to decreased ACE2 levels and functions in different tissues [135] (reviewed in [18]). Although low levels of ACE2 [135] expect to decrease the risk of SARS-CoV-2 infection, 75–85% of hospitalized patients were above the age of 50 years [19,133]. This higher morbidity and mortality in the aged population is congruent with the increased number of senescent cells with deregulated cell volume as a result of aging [136]. Hypertension, obesity, and diabetes also have preexisting deregulation of the RAS system [18]. Moreover, in diabetes, the influx of the major organic osmolyte glucose is already compromised, and the hijacking of remaining ACE2 by SARS-CoV-2 could facilitate osmotic collapse. Recently, genome-wide association analysis was performed in more than 1500 COVID-19 patients with ARDS and respiratory failure and population-based controls [137]. A significantly higher frequency of the risk allele for severe COVID-19 was found on chromosome 3, which codes for the SIT1 amino acid transporter as well as receptors for inflammatory cytokines, CC-motif chemokine receptor 9 (CCR9) and the C-X-C motif chemokine receptor 6 (CXCR6) among other genes [137]. This finding highlights an importance of the ACE2 partner SIT1 in the development of severe symptoms of COVID-19. Addressing intracellular tonicity could provide a missing link preventing microthrombotic complications, respiratory malfunction, and multi-organ failure.
6.4. Sensory and Neuronal Interplay of ENaC, ACE2, and TMPRSS2 in COVID-19

ENaC-dependent cell polarization plays a central role in the regulation of sensory input in neurons. Physiological ENaC levels in epithelial membranes were implicated in sensing the taste of salt and acid [138–141] transduced by gustatory chorda tympani (CT), which also express AT1R [139]. Na\(^+\) influx in tastebuds elicits suprathreshold depolarization activating voltage-gated neurotransmission by calcium homeostasis modulator 1 and 3 (CALHM1/3) [142]. Deficiency in αENaC abolishes salt taste in mice [143]. Stimulation with Ang II [144] or inflammatory mediators TNFα and LPS [145], reversibly decreases salt taste sensitivity in an activated ENaC-dependent fashion, even though other voltage-dependent and independent mechanisms for Na\(^+\) influx are also involved [145]. The mechanism underlying odor sensitivity is less clear, even though TMPRSS2, ACE2, and ENaC are expressed in nasal epithelial cells [48,146] in olfactory epithelium and, to a lesser extent, in olfactory neurons in an age-dependent manner [147]. ENaC amplifies the perception of odors, at least, in drosophila [146,148]. TMPRSS2, ACE2, and ENaC are also expressed in the tongue [138,149,150]. Hyperactivation of ENaC may present a plausible effector mechanism for altered sensory perception during stress.

Neurons of mammalians with high cognitive performance express δENaC in all regions in the brain, particularly in the cerebellum and hippocampus, as well as heart, and pancreas [151]. Low pH activates δENaC, which triggers H\(^+\) influx and a current, resulting in neuron desensitization [151] and ATP secretion [152]. EDTA, hypo-osmolarity, and lactate δENaC augment this response, suggesting its upregulation under hypoxic and/or inflammatory conditions [153]. In humans, αβγδENaC influences presynaptic plasticity resting membrane potential and excitability of neurons [154,155]. Aldosterone also activates ENaC in neurons [156] by PKC, which negates the actions of glucocorticoid-induced kinase 1 [157]. ENaC activity generates tonic changes in membrane potential responsible for basal firing in vasopressin and oxytocin neurons [155], and contributes to the neuroregulation of hypertension [158]. Despite evidence of ENaC’s role in control of fundamental neuronal functions, in vivo data remains scarce. Activation of ENaC in haploinsufficient Nedd4L\(^−/−\) mice [159] was associated with hyperactivity and increased sensitivity to inflammation-associated pain; however, neither ENaC nor its co-activated Cav3.2 calcium channel [160] were examined in this study. TMPRSS2 is also expressed at low levels in the brain, particularly in the pituitary gland and cerebellum [161] that also express αβγδENaC and ACE2. Cleaved forms of TMPRSS2 bind to protease-activated receptor 2 to induce Ca\(^{2+}\) influx, which regulates pain and allodynia in patients with cancers expressing TMPRSS2 [162]. The role of TMPRSS2 in the brain remains unknown. ACE2 is enzymatically active in the human brain [163] and its impact on anxiety-like behavior mediated by AngII/AT1R [164]. Overexpression of Ace2 altered the frequency of spontaneous inhibitory postsynaptic currents regulating GABA release onto GABAergic neurons in the basolateral amygdala [165]; however, the dependence of these currents on ENaC remains to be determined. Inhibition of Ang 1–7/MasR abolishes this effect [165]. ACE2 also decreases stress-activated hypothalamic-pituitary-adrenal (HPA) axis in males [166], but not in females [167]. Thus, catalytically active ACE2 switches anxiogenic effects of Ang II to anxiolytic responses of Ang 1–7 by an effector mechanism modulating postsynaptic currents.

SARS-CoV has been detected in the brain [168] and SARS-CoV-2 invasion has been proposed based on an in vitro study [169]. Recent study reports the presence of SARS-CoV-2 in the brains of transgenic mice that overexpress human ACE2, and in human cortical neurons post-mortem [170]. Cantuti-Castelvetri et al. have proposed an alternative neurophilin-1 (NRP1) pathway for SARS-CoV-2 entry into the sensory epithelium and, possibly, neural tissues [171]. In this study, S protein was detected in the olfactory epithelium and neuronal progenitors in five of the six examined tissues isolated from COVID-19 patients post-mortem [171]. However, in the absence of viral mRNA expression in these cells, the replication efficacy of SARS-CoV-2 in the context of NRP1 remains unclear. Interestingly, the detection of SARS-CoV-2 has been challenging [170,171], although patients infected with SARS-CoV-2 manifest neurological symptoms at early onset and throughout COVID-19 pathogenesis [172,173]. An array of neurological symptoms was provoked by SARS-CoV infections (reviewed in [172,173]). While host machinery, including ACE2 and TMPRSS2, supports the similar
entrance \[99,102\], inflammation, and hypoxia across coronavirus infections (reviewed in \[174\]), neurological manifestations in sensory and nervous tissues are distinct in COVID-19 \[175,176\]. Noteworthy, COVID-19 symptoms may be resultant of not only direct invasion of CNS, but also collateral damage of respiratory and cardiovascular systems, or neurohypertension \[177\]. The important difference between SARS-CoV-2 and SARS-CoV is also an ENaC-mediated polarization in sensory cells and neurons. Self-reported data collected in a cross-sectional study reports the loss of smell (anosmia) and taste (hypogeusia) that preceded the onset of the systemic and more severe disease symptoms \[176,178\] (reviewed in \[179\]). These observations agree with the role of ENaC in the mediation of salt and acid taste \[139\]. Polyneuritis cranialis or convulsions in COVID-19 patients \[172,173\] can reflect ENaC and TMPRSS2 malfunctions in trigeminal neurons. The anticipated impact of SARS-CoV-2 intercepting ACE2, TMPRSS2, and ENaC could provide a mechanistic cue to severe anxiety and increase in suicidal tendencies in COVID-19 patients \[180\], which are commonly attributed to isolation during hospitalization. Future investigations will determine the requirements for the treatment of these conditions. As the syndromic complexity of SARS-CoV-2 infection continues to evolve, the collection of data documenting electrolyte balance may unravel mechanisms of sensory and neuronal damage.

7. SARS-CoV-2 Furin Cleavage Site and Infectivity

The cleavage of S1/S2 proteins at the acquired furin site \[106\] has been proposed to explain an increase in infectivity of SARS-CoV-2 vs. SARS-CoV \[104,107\]. This cleavage elicits fusion of a SARS-CoV-2 infected cell with an uninfected cell, forming syncytium \[104\]. The formation of filopodia containing processed SARS-CoV-2 has been shown to propagate infection in a Caco2 cell culture by casein kinase 2-dependent activation of the cytoskeleton \[181\], whereas the relation to furin was not examined. Furin-mediated cleavage was sufficient to propagate infection in pulmonary cells; however, TMPRSS2 and other proteases can facilitate fusion of infected and uninfected cells \[104\]. SARS-CoV-2 predominantly invades pneumocytes (90%) and is present to a minor extent in other cell types \[50\]. Infected pneumocytes were distributed peripherally and involved upper and middle lung lobes, according to multiple studies comparing pneumonia in COVID-19 with other viral pneumonias \[182\]. This pattern of pneumonia in COVID-19 patients appears to be in support of cell-to-cell transmission \[104\] rather than the exposure of multiple cells to SARS-CoV-2. It remains to be investigated if cell-to-cell infection is responsible for the long, 14-day incubation period prior to the manifestation of COVID-19 symptoms.

Both furin inhibitors \[104\] and CK2 inhibitors \[181\] were suggested to prevent cell-to-cell SARS-CoV-2 infections, although serious side effects are anticipated from these unspecific therapies. Regulation of cholesterol content in membranes can be another way to control furin activity and ACE2 shedding. SARS-CoV and ACE2 reside in cholesterol-rich \[183\] lipid rafts, which elicit their endocytosis in the host cell \[183\]. Cholesterol-enriched rafts are also an obligate environment for furin-mediated cleavage of different substrates, including ADAM17 and collagen XXIII \[184,185\]. The loss of cholesterol directly impacts inflammation and induces ACE2 shedding by ADAM17 \[184,186\]. Although the extent of furin inhibition and facilitation of ACE2 shedding in a SARS-CoV-2 infected cells relative to other proposed mechanisms \[187,188\] needs to be examined further, a retrospective study demonstrated reduction of all-cause mortality from 9.4% to 5.2% in COVID-19 patients receiving cholesterol-lowering therapy with statins \[189\]. Other studies confirm this effect \[190\]. The efficacy of intervention involving delivery of statins directly into lungs vs. systemic inhibition of cholesterol synthesis requires further investigation.

The therapeutic inhibition of TMPRSS2 is commonly proposed as a strategy to prevent entry of viruses that require serine protease cleavage \[102,191\]. Protease inhibitors, including camostat mesylate, gabexate, and aprotinin, predominantly have a broad range of specificity \[102,191,192\] and elicit notable antifibrinolytic side effects \[193\]. The lack of any pathological manifestations in TMPRSS2\(^{-/-}\) mice \[194\] draws interest to therapeutic inhibition of TMPRSS2 as a possible safe target to decrease SARS-CoV-2 transmission \[102\]. The evidence that hypokalemia triggers expression of
TMPRSS2 suggests potassium supplementation as a promising strategy to prevent loss of $K^+$, lung hypertension, normalize cell volume, and prevent TMPRSS2-dependent viral infectivity.

8. Conclusions

The evolutionary success of viruses is determined by their ability to intercept critical signaling hubs of the host organism, which are centered on a multifunctional protein with a remarkable capacity to interact with other partner proteins governing host metabolism and immunity. The unprecedented morbidity of SARS-CoV-2 is based on its ability to occupy two hubs. The interception of ACE2 hub (Figure 5) is accompanied by overproduction of Ang II and destabilization of glucose and amino acids’ transport for nutritional and osmotic functions, that are required to resolve inflammation. The structural decoy-site on SARS-CoV-2 [21] enables an overactive state of host ENaC that further disrupts local and systemic osmotic and ionic homeostasis, as well as polarization in neurons, barrier, and sensory cells (Figure 4). Experimental and clinical studies need to validate this mechanism. However, the presence of E protein on all beta coronaviruses, which forms an ion channel with 10-fold higher permeability for Na$^+$ than for K$^+$ ions [195], suggests that regulation of ion concentrations is a fundamental requirement for replication of these pathogens. Hijacked together, ACE2 and ENaC hubs collapse cellular osmolality in COVID-19 patients that leads to ATP depletion and necrotic death or hypotonic rapture releasing LDH [196], microthrombosis [197], and hypoxia. Alone, therapeutics reducing Ang II levels and AT1R responses cannot alleviate SARS-CoV and SARS-CoV-2 complications [19]. The combinatorial onset of this osmotic crisis requires combinatorial therapies as effective solutions.

9. Therapeutic Perspectives

Arguably, the most important advantage of the acquired furin site is in redirecting TMPRSS2 function for proteolytic cleavage of SARS-CoV-2 (Figure 2C), opening a possibility of cell-to-cell propagation of infection [102,104] in seemingly asymptomatic patients [198] (reviewed in [19]). This special type of pathogenesis calls for alteration to standard therapeutic measures. COVID-19 patients receiving intravenous remdesivir recover only four days earlier than placebo control and have no reported data on patient survival [199]. Therapies inhibiting viral replication or inflammation reveal marginal efficacy (reviewed in [19]). Based on discussed interactions and infectivity data (reviewed in [19]), furin inhibitors [104] and CK2 inhibitors [181] are expected to be efficient during the first five days of asymptomatic infection. The encouraging decrease in mortality in the statin-treated group of COVID-19 patients [189] suggests that statins are a safe adjuvant therapy that decrease furin output and improve all stages of the disease. The attempt to treat COVID-19 patients with recombinant ACE2 [200] would likely be only partially effective in inhibition of cell-to-cell propagation mediated by TMPRSS2 and furin cleavage [102,104].

Hypokalemia found in COVID-19 patients in ~75% of COVID-19 cases [196] must be addressed in future clinical trials. Although initial potassium supplementation was performed in patients with severe COVID-19 manifestations [121], its impact on TMPRSS2 expression, ENaC activity, LDH levels, blood and urine osmolality, and the rate of viral replication has not been examined to validate the role of TMPRSS2/ENaC axes in the amplification of SARS-CoV-2 propagation and osmotic crisis. Future clinical studies need to be performed in COVID-19 patients including newly infected subjects and patients with severe pathogenesis, to elucidate the role of hypokalemia in increasing TMPRSS2 expression, which contributes to SARS-CoV-2 propagation and osmotic crisis. Cardiologic manifestations of COVID-19, microvascular and endothelial disease and heart failure [131] have been proposed as the critical mechanisms leading to COVID-19-related mortality [201,202]. The specific underlying mechanisms of endothelial damage beyond inflammation in COVID-19 patients have been established in clinical studies [20]; however, it remains elusive, because SARS-CoV-2 does not replicate in endothelial cells [51]. The osmotic crisis resulting from hypokalemia and disruption of the ACE2-based complex is compatible with clinical findings in damaged endothelial cells, early manifestations of elevated D-dimer levels, and the progression to thrombosis in COVID-19 patients. Current clinical trials use fibrinolytic and
anti-inflammatory therapies reviewed in [19] to combat thrombosis. To address osmotic crisis, adjuvant supplementation with neutral amino acids could be implemented to replenish organic osmolytes and stabilize intracellular osmolality when the ACE2 complex is disabled. This safe approach improves the rate of distress, executive functions, attention, and vigilance in patients with genetic disorders and malnutrition [203]. Normalization of hypokalemia, resulting from the hyperactivation of ENaC, could be achieved by a moderate dose of amiloride combined with potassium and neutral amino acids’ supplementation to address both the root problem and its consequences.

More therapeutic options may be developed in the future using recombinant chimeric protein technology. Apelin can compete with the virus for binding to ACE2 and participate in the resolution of inflammation and hypoxia [204]. The soluble TMPRSS2 or a chimeric protein combining the catalytic sites of ACE2, TMPRSS2, and the furin site of ENaC, may serve as a decoy for the virus and mediate its cleavage directly in circulation. Breakthrough in management of hypertension was made following discovery of RAS pathway. COVID-19 pathology prompts us to understand the versatile biology of ACE2-complex and its ENaC counterpart in the regulation of intracellular osmosis that could also shed light on complications of metabolic degenerative diseases, such as aging and diabetes. The most remarkable feature of COVID-19 is the range of host responses to the infection [132,133] indicating that the host response is the main culprit in morbidity and mortality. Decipherment of dynamic interactions among proteins within host signaling hubs may be the ground for development of effective therapies for infectious and degenerative metabolic diseases.

10. Patents

There are no patents resulting from the work reported in this manuscript.

Author Contributions: D.M., S.R.A. and S.B.K. investigated published materials, wrote sections of the manuscript and edited it, as well as draw the figures. O.Z. conceptualized concepts, figures and manuscript, investigated materials and wrote manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: The project was supported by NIH, the National Center for Research Resources UL1RR025755 and NCI P30CA16058 (OSUCCC), the NIH Roadmap for Medical Research. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources or the National Institutes of Health. This work was supported by the Falk Trust Award. S.B.K.’s work was supported by Long Term ICMR-DHR International Fellowship for Young Bio-medical Scientists 2019–20, office order No. INDO/FRC/452 (Y-60)/2019-20-IHD.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Abbreviations

| Abbreviation | Description |
|--------------|-------------|
| AA           | Amino Acids |
| ACE          | Angiotensin-converting enzyme |
| ACE2         | Angiotensin-converting enzyme 2 |
| ADAM17       | Disintegrin and metalloproteinase 17 (Alias: TACE) |
| AMPK         | Adenosine monophosphate-activated protein kinase |
| Ang II       | Angiotensin II (Alias: Ang 1–8) |
| Ang (1–10)   | Angiotensin I |
| AP1          | Activator protein 1 transcription factor |
| AQP1         | Aquaporin 1, a water channel protein |
| AT1R         | Angiotensin II Type 1 Receptor |
| APJ          | Apelin receptor |
| ARDS         | Acute Respiratory Distress Syndrome |
| ASCT2        | Alanine, serine, cysteine-preferring transporter 2 (gene SLC1A5) |
| AVP          | Arginin vasopressin |
| B0AT1        | B degrees amino acid transporter 1 (gene SLC6A19) |
| CALHM1/3     | Calcium homeostasis modulator 1 and 3 |
| Abbreviation | Definition |
|--------------|------------|
| CAM          | Calmodulin |
| CAMKII       | CaM-dependent kinase |
| CAP1         | Channel-activating protease |
| CatA         | Cathepsin A |
| CK2          | Casein kinase 2 |
| CNS          | Central nervous system |
| COX2         | Cyclooxygenase 2 |
| COVID-19     | Coronavirus Disease of 2019 |
| CRP          | C-reactive protein |
| CT           | Chorda tympani |
| DAG          | Diacylglycerol |
| ECM          | Extracellular matrix |
| EDTA         | Ethylenediaminetetraacetic acid |
| ENaC         | Epithelial sodium channel |
| ER           | Endoplasmic reticulum |
| Gαq/11       | Guanine nucleotide binding protein (G protein), alpha 11 (Gq class) |
| GABA         | Gamma-aminobutyric acid |
| GDP          | Guanosine diphosphate |
| Glu          | Glucose |
| GLUT1        | Glucose transporter 1 |
| GTP          | Guanosine triphosphate |
| HAT          | Transmembrane serine protease 11D (Alias: TMPRSS11D) |
| H1N1         | Influenza A |
| HCoV-NL63    | Human coronavirus NL63 |
| HIF1         | Hypoxia Induced Transcription Factor |
| HMOX1        | Heme Oxygenase-1 |
| HPA          | Hypothalamic-pituitary-adrenal |
| iAA          | Imino acids, e.g., proline |
| IP3          | Inositol 3 phosphate |
| LDH          | Lactate dehydrogenase (Alias: Lactic acid dehydrogenase) |
| LPS          | Lipopolysaccharide |
| MAS          | MAS1 proto-oncogene, G protein-coupled receptor |
| mTORC1       | Mammalian target of rapamycin complex 1 (Alias: Mechanistic target of rapamycin complex 1) |
| nAA          | Neutral amino acids |
| NFAT5        | Nuclear Factor of Activated T cells (Alias: TonEBP, tonicity-responsive enhancer binding protein) |
| NHE3         | Sodium–hydrogen exchanger 3 |
| NO/iNOS      | Nitric Oxide |
| ORF8         | Envelope glycoprotein B (Gene: ORF8) |
| PAI-1        | Plasminogen Activator Inhibitor-1 |
| PKC          | Protein kinase C |
| PLC          | Phospholipase C |
| RAS          | Renin-Angiotensin System |
| RBD          | Receptor binding domain |
| ROS          | Reactive Oxygen Species |
| sACE2        | Soluble angiotensin-converting enzyme 2 |
| SARS-CoV     | Severe Acute Respiratory Syndrome Coronavirus |
| SARS-CoV-2   | Severe Acute Respiratory Syndrome Coronavirus 2 |
| SGK1.1       | Glucocorticoid-induced kinase 1 |
| SGLT1        | Sodium-dependent Glucose Transporter 1 |
SIT1 Sodium/Imino-acid Transporter 1 (gene: SLC6A20)
SLC6A19 Solute Carrier Family 6 Member 19 (protein BoAT1)
TACE Tumor Necrosis Factor-α Converting Enzyme (Alias: ADAM 17)
TAPI2 TNF Protease Inhibitor 2
TMEM27 Transmembrane protein 27 (Alias: Collectrin, Gene: CLTRN)
TMPRSS2 Transmembrane Serine Protease 2
VP Vasopressin
vWF von Willebrand factor
WT Wild type

References
1. Hartenian, E.; Nandakumar, D.; Lari, A.; Ly, M.; Tucker, J.M.; Glaunsinger, B.A. The molecular virology of Coronaviruses. *J. Biol. Chem.* 2020, 295, 12910–12934. [CrossRef]
2. Dell’Italia, L.J. Translational success stories: Angiotensin receptor 1 antagonists in heart failure. *Circ. Res.* 2011, 109, 437–452. [CrossRef]
3. Kai, H.; Kai, M. Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors—lessons from available evidence and insights into COVID-19. *Hypertens. Res.* 2020, 43, 648–654. [CrossRef]
4. Dostal, D.E.; Baker, K.M. The cardiac renin-angiotensin system: Conceptual, or a regulator of cardiac function? *Circ. Res.* 1999, 85, 643–650. [CrossRef]
5. Bader, M.; Alenina, N.; Young, D.; Santos, R.A.S.; Touyz, R.M. The Meaning of Mas. *Hypertension* 2018, 72, 1072–1075. [CrossRef]
6. South, A.M.; Shaltout, H.A.; Washburn, L.K.; Hendricks, A.S.; Diz, D.I.; Chappell, M.C. Fetal programming and the angiotensin-(1-7) axis: A review of the experimental and clinical data. *Clin. Sci.* 2019, 133, 55–74. [CrossRef]
7. Ferrario, C.M. Angiotensin-converting enzyme 2 and angiotensin-(1-7): An evolving story in cardiovascular regulation. *Hypertension* 2006, 47, 515–521. [CrossRef]
8. Crackower, M.A.; Sarao, R.; Oudit, G.Y.; Yagil, C.; Kozieradzki, I.; Scanga, S.E.; Oliveira-dos-Santos, A.J.; da Costa, J.; Zhang, L.; Pei, Y.; et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. *Nature* 2002, 417, 822–828. [CrossRef]
9. Singer, D.; Camargo, S.M.; Ramadan, T.; Schafer, M.; Mariotta, L.; Herzog, B.; Huggel, K.; Wolfer, D.; Werner, S.; Penninger, J.M.; et al. Defective intestinal amino acid absorption in Ace2 null mice. *Am. J. Physiol. Gastrointest. Liver Physiol.* 2012, 303, G686–G695. [CrossRef]
10. Camargo, S.M.; Singer, D.; Makrides, V.; Huggel, K.; Pos, K.M.; Wagner, C.A.; Kuba, K.; Danilczuk, U.; Skovby, F.; Kleta, R.; et al. Tissue-specific amino acid transporter partners ACE2 and collectrin differentially interact with hartnup mutations. *Gastroenterology* 2009, 136, 872–882. [CrossRef]
11. Kowalczuk, S.; Broer, A.; Tietze, N.; Vanslambrouck, J.M.; Rasko, J.E.; Broer, S. A protein complex in the brush-border membrane explains a Hartnup disorder allele. *FASEB J.* 2008, 22, 2880–2887. [CrossRef]
12. Yan, R.; Zhang, Y.; Li, Y.; Xia, L.; Guo, Y.; Zhou, Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. *Science* 2020, 367, 1444–1448. [CrossRef]
13. Lambert, D.W.; Yarksi, M.; Warner, F.J.; Thornhill, P.; Parkin, E.T.; Smith, A.I.; Hooper, N.M.; Turner, A.J. Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). *J. Biol. Chem.* 2005, 280, 30113–30119. [CrossRef]
14. Clarke, N.E.; Fisher, M.J.; Porter, K.E.; Lambert, D.W.; Turner, A.J. Angiotensin converting enzyme (ACE) and ACE2 bind integrins and ACE2 regulates integrin signalling. *PLoS ONE* 2012, 7, e34747. [CrossRef]
15. Wrapp, D.; Wang, N.; Corbett, K.S.; Goldsmith, J.A.; Hsieh, C.L.; Abiona, O.; Graham, B.S.; McLellan, J.S. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. *Science* 2020, 367, 1260–1263. [CrossRef]
16. Sui, J.; Li, W.; Murakami, A.; Tamin, A.; Matthews, L.J.; Wong, S.K.; Moore, M.J.; Tallarico, A.S.; Olurinde, M.; Choe, H.; et al. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. *Proc. Natl. Acad. Sci. USA* 2004, 101, 2536–2541. [CrossRef]

17. Available online: https://coronavirus.jhu.edu/map.html (accessed on 1 October 2020).

18. Verdecchia, P.; Cavallini, C.; Spanevello, A.; Angeli, F. The pivotal link between ACE2 deficiency and SARS-CoV-2 infection. *Eur. J. Intern. Med.* 2020, 76, 14–20. [CrossRef]

19. Wiersinga, W.J.; Rhodes, A.; Cheng, A.C.; Peacock, S.J.; Prescott, H.C. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. *JAMA 2020*, 324, 749–751. [CrossRef]

20. Ackermann, M.; Verleden, S.E.; Kuehnel, M.; Haverich, A.; Welte, T.; Laenger, F.; Vansapel, A.; Werlein, C.; Stark, H.; Tzankov, A.; et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. *N. Engl. J. Med.* 2020, 383, 120–128. [CrossRef]

21. Anand, P.; Puranik, A.; Aravamudan, M.; Venkatakrishnan, A.J.; Soundararajan, V. SARS-CoV-2 strategically mimics protolytic activation of human ENaC. *Elife* 2020, 9, e58603. [CrossRef]

22. Tipnis, S.R.; Hooper, N.M.; Hyde, R.; Karran, E.; Christie, G.; Turner, A.J. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. *J. Biol. Chem.* 2000, 275, 33238–33243. [CrossRef]

23. Donoghue, M.; Hsieh, F.; Baronas, E.; Godbout, K.; Gosselin, M.; Stagliano, N.; Donovan, M.; Woolf, B.; Robison, K.; Jeyaseelan, R.; et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. *Circ. Res.* 2000, 87, E1–E9. [CrossRef]

24. Vickers, C.; Hales, P.; Kaushik, V.; Dick, L.; Gavin, J.; Tang, J.; Godbout, K.; Parsons, T.; Baronas, E.; Hsieh, F.; et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. *J. Biol. Chem.* 2002, 277, 14838–14843. [CrossRef]

25. Heurich, A.; Hofmann-Winkler, H.; Gierer, S.; Liepold, T.; Jahn, O.; Pohlmann, S. TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein. *J. Virol.* 2014, 88, 1293–1307. [CrossRef]

26. Freis, E.D. Salt, volume and the prevention of hypertension. *Circulation* 1976, 53, 589–595. [CrossRef]

27. Butterworth, M.B. Regulation of the epithelial sodium channel (ENaC) by membrane trafficking. *Biochim. Biophys. Acta* 2010, 1802, 1166–1177. [CrossRef]

28. Veiras, L.C.; McFarlin, B.E.; Ralph, D.L.; Buncha, V.; Prescott, J.; Shirvani, B.S.; McDonough, J.C.; Ha, D.; Giani, J.; Gurley, S.B.; et al. Electrolyte and transporter responses to angiotensin II induced hypertension in female and male rats and mice. *Acta Physiol.* 2020, 229, e13448. [CrossRef]

29. Li, X.C.; Shao, Y.; Zhuo, J.L. AT1a receptor signaling is required for basal and water deprivation-induced urine concentration in AT1a receptor-deficient mice. *Am. J. Physiol. Ren. Physiol.* 2012, 303, F746–F756. [CrossRef]

30. Mamenko, M.; Zaika, O.; Prieto, M.C.; Jensen, V.B.; Doris, P.A.; Navar, L.G.; Pochynyuk, O. Chronic angiotensin II infusion drives extensive aldosterone-independent epithelial Na⁺ channel activation. *Hypertension* 2013, 62, 1111–1122. [CrossRef]

31. Peti-Peterdi, J.; Warnock, D.G.; Bell, P.D. Angiotensin II directly stimulates ENaC activity in the cortical collecting duct via AT(1) receptors. *J. Am. Soc. Nephrol.* 2002, 13, 1131–1135. [CrossRef]

32. Boscardin, E.; Alijevic, O.; Hummler, E.; Frateschi, S.; Kellenberger, S. The function and regulation of acid-sensing ion channels (ASICs) and the epithelial Na(+) channel (ENaC): IUPHAR Review 19. *Br. J. Pharmacol.* 2016, 173, 2671–2701. [CrossRef]

33. Mobasher, A.; Wray, S.; Marples, D. Distribution of AQP2 and AQP3 water channels in human tissue microarrays. *J. Mol. Histol.* 2005, 36, 1–14. [CrossRef]

34. Miteva, D.O.; Rutkowski, J.M.; Dixon, J.B.; Kilarski, W.; Shields, J.D.; Swartz, M.A. Transmural flow modulates cell and fluid transport functions of lymphatic endothelium. *Circ. Res.* 2010, 106, 920–931. [CrossRef]

35. Wittekindt, O.H.; Dietl, P. Aquaporins in the lung. *Pfuigers Arch.* 2019, 471, 519–532. [CrossRef]

36. Zhang, W.; Zitron, E.; Homme, M.; Kihm, L.; Morath, C.; Scherer, D.; Hegge, S.; Thomas, D.; Schmitt, C.P.; Zeier, M.; et al. Aquaporin-1 channel function is positively regulated by protein kinase C. *J. Biol. Chem.* 2007, 282, 20933–20940. [CrossRef]
37. Weber, J.; Rajan, S.; Schremmer, C.; Chao, Y.K.; Krasteva-Christ, G.; Kannler, M.; Yildirim, A.O.; Brosien, M.; Schredelseker, J.; Weissmann, N.; et al. TRPV4 channels are essential for alveolar epithelial barrier function as protection from lung edema. *JCI Insight* 2020. [CrossRef]

38. Li, H.; Kan, H.; He, C.; Zhang, X.; Yang, Z.; Jin, J.; Zhang, P.; Ma, X. TRPV4 activates cytosolic phospholipase A2 via Ca(2+)-dependent PKC/ERK1/2 signalling in controlling hypertensive contraction. *Clin. Exp. Pharmacol. Physiol.* 2018. [CrossRef]

39. Namkung, W.; Song, Y.; Mills, A.D.; Padmawar, P.; Finkbeiner, W.E.; Verkman, A.S. In situ measurement of airway surface liquid [K+] using a ratioable K+-sensitive fluorescent dye. *J. Biol. Chem.* 2009, 284, 15916–15926. [CrossRef] [PubMed]

40. Cook, D.I.; Dinudom, A.; Komwatana, P.; Kumar, S.; Young, J.A. Patch-clamp studies on epithelial sodium channels in salivary duct cells. *Cell Biochem. Biophys.* 2002, 36, 105–113. [CrossRef]

41. Knoepp, F.; Ashley, Z.; Barth, D.; Baldwin, J.P.; Jennings, M.; Kazantseva, M.; Saw, E.L.; Kate, R.; Alvarez de la Rosa, D.; Weissmann, N.; et al. Shear force sensing of epithelial Na(+) channel (ENaC) relies on N-glycosylated asparagines in the palm and knuckle domains of alphaENaC. *Proc. Natl. Acad. Sci. USA* 2020, 117, 717–726. [CrossRef]

42. Biffi, G.; Tannahill, D.; McCafferty, J.; Balasubramanian, S. Quantitative visualization of DNA G-quadruplex structures in human cells. *Nat. Chem.* 2013, 5, 182–186. [CrossRef] [PubMed]

43. Seenisamy, J.; Rezler, E.M.; Powell, T.J.; Tye, D.; Gokhale, V.; Joshi, C.S.; Siddiqui-Jain, A.; Hurley, L.H. The dynamic character of the G-quadruplex element in the c-MYC promoter and modification by TMPyP4. *J. Am. Chem. Soc.* 2004, 126, 8702–8709. [CrossRef] [PubMed]

44. Shen, L.W.; Qian, M.Q.; Yu, K.; Narva, S.; Yu, F.; Wu, Y.L.; Zhang, W. Inhibition of Influenza A virus propagation by benzozelenoanthenes stabilizing TMPRSS2 Gene G-quadruplex and hence down-regulating TMPRSS2 expression. *Sci. Rep.* 2020, 10, 7635. [CrossRef] [PubMed]

45. Balasubramanian, S.; Neidle, S. G-quadruplex nucleic acids as therapeutic targets. *Curr. Opin. Chem. Biol.* 2009, 13, 345–353. [CrossRef] [PubMed]

46. Donaldson, S.H.; Hirsh, A.; Li, D.C.; Holloway, G.; Chao, J.; Boucher, R.C.; Gabriel, S.E. Regulation of the epithelial sodium channel by serine proteases in human airways. *J. Biol. Chem.* 2002, 277, 8338–8345. [CrossRef] [PubMed]

47. Afar, D.E.; Vivanco, I.; Hubert, R.S.; Kuo, J.; Chen, E.; Saffran, D.C.; Raitano, A.B.; Jakobovits, A. Catalytic cleavage of the androgen-regulated TMPRSS2 protease results in its secretion by prostate and prostate cancer epithelia. *Cancer Res.* 2001, 61, 1686–1692.

48. Ziegler, C.G.K.; Allon, S.J.; Nyquist, S.K.; Mbano, I.M.; Miao, V.N.; Tzouanas, C.N.; Cao, Y.; Yousif, A.S.; Bals, J.; Hauser, B.M.; et al. SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues. *Cell 2020*, 181, 1016–1035. [CrossRef]

49. Liu, Y.; Jiang, B.J.; Zhao, R.Z.; Ji, H.L. Epithelial Sodium Channels in Pulmonary Epithelial Progenitor and Stem Cells. *Int. J. Biol. Sci.* 2016, 12, 1150–1154. [CrossRef]

50. Carsana, L.; Sonzogni, A.; Nasr, A.; Rossi, R.S.; Pellegrinelli, A.; Zerbi, P.; Rech, R.; Colombo, R.; Antinori, S.; Corbello, M.; et al. Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: A two-centre descriptive study. *Lancet Infect. Dis.* 2020, 20, 1135–1140. [CrossRef]

51. Damiani, S.; Fiorentino, M.; De Palma, A.; Foschini, M.P.; Lazzarotto, T.; Gabrielli, L.; Viale, P.L.; Attard, L.; Riefolo, M.; D’Errico, A. Pathological Post Mortem Findings in Lungs Infected With Sars-Cov 2. *J. Pathol.* 2020. [CrossRef]

52. Solymosi, E.A.; Kaestle-Gembardt, S.M.; Vadasz, I.; Wang, L.; Neye, N.; Chupin, C.J.; Rozowsky, S.; Ruehl, R.; Tabuchi, A.; Schulz, H.; et al. Chloride transport-driven alveolar fluid secretion is a major contributor to cardiogenic lung edema. *Proc. Natl. Acad. Sci. USA* 2013, 110, E2308–E2316. [CrossRef]

53. Veiras, L.C.; Han, J.; Ralph, D.L.; McDonough, A.A. Potassium Supplementation Prevents Sodium Chloride Cotransporter Stimulation During Angiotensin II Hypertension. *Hypertension 2016*, 68, 904–912. [CrossRef] [PubMed]

54. Wu, P.; Gao, Z.X.; Duan, X.P.; Su, X.T.; Wang, M.X.; Lin, D.H.; Gu, R.; Wang, W.H. AT2R (Angiotensin II Type 2 Receptor)-Mediated Regulation of NCC (Na-Cl Cotransporter) and Renal K Excretion Depends on the K Channel, Kir4.1. *Hypertension 2018*, 71, 622–630. [CrossRef]
55. Planes, C.; Caughhey, G.H. Regulation of the epithelial Na+ channel by peptidases. Curr. Top. Dev. Biol. 2007, 78, 23–46.
56. Kimura, T.; Kawabe, H.; Jiang, C.; Zhang, W.; Xiang, Y.Y.; Lu, C.; Salter, M.W.; Brose, N.; Lu, W.Y.; Rotin, D. Deletion of the ubiquitin ligase Nedd4L in lung epithelia causes cystic fibrosis-like disease. Proc. Natl. Acad. Sci. USA 2011, 108, 3216–3221. [CrossRef]
57. Goel, P.; Manning, J.A.; Kumar, S. NEDD4-2 (NEDD4L): The ubiquitin ligase for multiple membrane proteins. Gene 2015, 557, 1–10. [CrossRef]
58. Namkung, Y.; LeGouill, C.; Kumar, S.; Cao, Y.; Teixeira, L.B.; Lukasheva, V.; Giubilaro, J.; Simoes, S.C.; Petersen, J.S. Congestive heart failure in rats is associated with increased expression and targeting of the epithelial Na+ channel by Nedd4 in Liddle’s syndrome. J. Clin. Investig. 1999, 103, 667–673. [CrossRef]
59. Wynne, B.M.; Zou, L.; Linck, V.; Hoover, R.S.; Ma, H.P.; Eaton, D.C. Regulation of Lung Epithelial Sodium Channels by Cytokines and Chemokines. Front. Immunol. 2017, 8, 766. [CrossRef] [PubMed]
60. Bussolati, O.; Dall’Asta, V.; Franchi-Gazzola, R.; Sala, R.; Rotoli, B.M.; Visigalli, R.; Casado, J.; Lopez-Fontanals, M.; Pastor-Anglada, M.; Gazzola, G.C. The role of system A for neutral amino acid transport in the regulation of cell volume. Mol. Membr. Biol. 2001, 18, 27–38. [CrossRef] [PubMed]
61. Wong, T.P.; Debnam, E.S.; Leung, P.S. Involvement of an enterocyte renin-angiotensin system in the local control of SGLT1-dependent glucose uptake across the rat small intestinal brush border membrane. J. Physiol. 2007, 584, 613–623. [CrossRef]
62. Tanemoto, M. Effect of serum albumin on serum sodium: Necessity to consider the Donnan effect. QJM 2008, 101, 827–828. [CrossRef]
63. Dunn, M.J. The roles of angiotensin II and prostaglandins in the regulation of the glomerular filtration of albumin. J. Hypertens. Suppl. 1990, 8, S47–S51. [CrossRef]
64. Lim, S.C.; Liu, J.J.; Subramaniam, T.; Sum, C.F. Elevated circulating alpha-klotho by angiotensin II receptor blocker losartan is associated with reduction of albuminuria in type 2 diabetic patients. J. Renin Angiotensin Aldosterone Syst. 2014, 15, 487–490. [CrossRef]
65. Kim, H.J.; Sato, T.; Rodriguez-Iturbe, B.; Vaziri, N.D. Role of intrarenal angiotensin system activation, oxidative stress, inflammation, and impaired nuclear factor-erythroid-2-related factor 2 activity in the progression of focal glomerulosclerosis. J. Pharmacol. Exp. Ther. 2011, 337, 583–590. [CrossRef]
66. Dandona, P.; Fonseca, V.; Baron, D.N. Hypoalbuminaemic hyponatraemia: A new syndrome? Br. Med. J. 1985, 291, 1253–1255. [CrossRef]
67. Namkung, Y.; LeGouill, C.; Kumar, S.; Cao, Y.; Teixeira, L.B.; Lukasheva, V.; Giubilaro, J.; Simoes, S.C.; Longpre, J.M.; Devost, D.; et al. Functional selectivity profiling of the angiotensin II type 1 receptor using pathway-wide BRET signaling sensors. Sci. Signal. 2018, 11, eaat1631. [CrossRef]
68. Redig, A.J.; Platanias, L.C. The protein kinase C (PKC) family of proteins in cytokine signaling in hematopoiesis. J. Interferon Cytokine Res. 2007, 27, 623–636. [CrossRef]
69. Conner, M.T.; Conner, A.C.; Brown, J.E.; Bill, R.M. Membrane trafficking of aquaporin 1 is mediated by protein kinase C via microtubules and regulated by tonicity. Biochemistry 2010, 49, 821–823. [CrossRef]
70. Kitchen, P.; Oberg, F.; Sjohamn, J.; Hedfalk, K.; Bill, R.M.; Conner, A.C.; Conner, M.T.; Tornroth-Horsefield, S. Plasma Membrane Abundance of Human Aquaporin 5 Is Dynamically Regulated by Multiple Pathways. PLoS ONE 2015, 10, e0143027. [CrossRef]
71. Li, C.; Wang, W.; Rivard, C.J.; Lanaspa, M.A.; Summer, S.; Schrier, R.W. Molecular mechanisms of angiotensin II stimulation on aquaporin-2 expression and trafficking. Am. J. Physiol. Ren. Physiol. 2011, 300, F1255–F1261. [CrossRef]
72. Nielsen, S.; Terris, J.; Andersen, D.; Ecelbarger, C.; Frokiaer, J.; Jonassen, T.; Marples, D.; Knepper, M.A.; Petersen, J.S. Congestive heart failure in rats is associated with increased expression and targeting of aquaporin-2 water channel in collecting duct. Proc. Natl. Acad. Sci. USA 1997, 94, 5450–5455. [CrossRef] [PubMed]
73. Schrier, R.W.; Martin, P.Y. Recent advances in the understanding of water metabolism in heart failure. Adv. Exp. Med. Biol. 1998, 449, 415–426. [PubMed]
74. Feng, Y.; Hans, C.; McIlwain, E.; Varner, K.J.; Lazartigues, E. Angiotensin-converting enzyme 2 over-expression in the central nervous system reduces angiotensin-II-mediated cardiac hypertrophy. PLoS ONE 2012, 7, e48910. [CrossRef] [PubMed]
75. Broer, A.; Juelich, T.; Vanslambrouck, J.M.; Tietze, N.; Solomon, P.S.; Holst, J.; Bailey, C.G.; Rasko, J.E.; Broer, S. Impaired nutrient signaling and body weight control in a Na+ neutral amino acid cotransporter (Slc6a19)-deficient mouse. J. Biol. Chem. 2011, 286, 26638–26651. [CrossRef]

76. Dos-Santos, R.C.; Monteiro, L.; Paes-Leme, B.; Lustrino, D.; Antunes-Rodrigues, J.; Mecawi, A.S.; Reis, L.C. Central angiotensin-(1-7) increases osmotic thirst. Exp. Physiol. 2017, 102, 1397–1404. [CrossRef]

77. Danilczyk, U.; Sarao, R.; Remy, C.; Benabbas, C.; Stange, G.; Richter, A.; Arya, S.; Pospisilik, J.A.; Singer, D.; Camargo, S.M.; et al. Essential role for collectrin in renal amino acid transport. Nature 2006, 444, 1088–1091. [CrossRef]

78. Seow, H.F.; Broer, S.; Broer, A.; Potter, S.J.; Cavanaugh, J.A.; Rasko, J.E. Hartnup disorder is caused by mutations in the gene encoding the neutral amino acid transporter SLC6A19. Nat. Genet. 2004, 36, 1003–1007. [CrossRef]

79. Baron, D.N.; Dent, C.E.; Harris, H.; Hart, E.W.; Jepson, J.B. Hereditary pellagra-like skin rash with temporary cerebellar ataxia, constant renal amino-aciduria, and other bizarre biochemical features. Lancet 1956, 271, 421–428. [CrossRef]

80. Vuille-dit-Bille, R.N.; Camargo, S.M.; Emmenegger, L.; Sasse, T.; Kummer, E.; Jando, J.; Hamie, Q.M.; Meier, C.F.; Hunziker, S.; Forras-Kaufmann, Z.; et al. Human intestine luminal ACE2 and amino acid transporter expression increased by ACE-inhibitors. Amino Acids 2015, 47, 693–705. [CrossRef]

81. Bernardi, S.; Tikellis, C.; Candido, R.; Tsorotes, D.; Pickering, R.; Bossi, F.; Carretta, R.; Fabris, B.; Cooper, M.E.; Thomas, M.C. ACE2 deficiency shifts energy metabolism towards glucose utilization. Metabolism 2015, 64, 406–415. [CrossRef]

82. Javed, K.; Broer, S. Mice Lacking the Intestinal and Renal Neutral Amino Acid Transporter SLC6A19 Demonstrate the Relationship between Dietary Protein Intake and Amino Acid Malabsorption. Nutrients 2019, 11, 2024. [CrossRef]

83. Pedersen, K.B.; Chhabra, K.H.; Nguyen, V.K.; Xia, H.; Lazartigues, E. The transcription factor HNF1alpha induces expression of angiotensin-converting enzyme 2 (ACE2) in pancreatic islets from evolutionarily conserved promoter motifs. Biochim. Biophys. Acta 2013, 1829, 1225–1235. [CrossRef]

84. Niu, M.J.; Yang, J.K.; Lin, S.S.; Ji, X.J.; Guo, L.M. Loss of angiotensin-converting enzyme 2 leads to impaired glucose homeostasis in mice. Endocrine 2008, 34, 56–61. [CrossRef] [PubMed]

85. van Twist, D.J.; Kroon, A.A.; de Leeuw, P.W. Angiotensin-(1-7) as a strategy in the treatment of hypertension? Curr. Opin. Nephrol. Hypertens. 2014, 23, 480–486. [CrossRef]

86. Zhang, F.; Tang, H.; Sun, S.; Luo, Y.; Ren, X.; Chen, A.; Xu, Y.; Li, P.; Han, Y. Angiotensin-(1-7) induced vascular relaxation in hypertensive rats. Nitric Oxide 2019, 88, 1–9. [CrossRef] [PubMed]

87. Ocaranza, M.P.; Moya, J.; Alzamora, R.; Higaki, T.; Ishii, E.; Horiuchi, M. ACE2 deficiency induced perivasculare fibrosis and cardiac hypertrophy during postnatal development in mice. J. Am. Soc. Hypertens. 2013, 7, 259–266. [CrossRef]

88. Garcia, L.; Novoa, U.; et al. Angiotensin-(1-9) reverses experimental hypertension and cardiovascular damage by inhibition of the angiotensin converting enzyme/Ang II axis. J. Hypertens. 2014, 32, 771–783. [CrossRef]

89. The Human Protein Atlas. Available online: https://www.proteinatlas.org/ENSG00000147003-CLTRN/tissue (accessed on 31 July 2020).

90. Giani, J.F.; Gironacci, M.M.; Munoz, M.C.; Pena, C.; Turyn, D.; Dominici, F.P. Angiotensin-(1-7) stimulates the phosphorylation of JAK2, IRS-1 and Akt in rat heart in vivo: Role of the AT1 and Mas receptors. Am. J. Physiol. Heart Circ. Physiol. 2007, 293, H1154–H1163. [CrossRef]

91. Xiao, H.D.; Fuchs, S.; Bernstein, E.A.; Li, P.; Campbell, D.J.; Bernstein, K.E. Mice expressing ACE only in the heart show that increased cardiac angiotensin II is not associated with cardiac hypertrophy. Am. J. Physiol. Heart Circ. Physiol. 2008, 294, H659–H667. [CrossRef]

92. Wilson, C.S.; Mongin, A.A. Cell Volume Control in Healthy Brain and Neuropathologies. Curr. Top. Membr. 2018, 81, 385–455. [PubMed]

93. Avissar, N.E.; Ryan, C.K.; Ganapathy, V.; Sax, H.C. Na(+)-dependent neutral amino acid transporter ATB(0) is a rabbit epithelial cell brush-border protein. Am. J. Physiol. Cell Physiol. 2001, 281, C963–C971. [CrossRef] [PubMed]
Biomedicines 2020, 8, 460

94. Ranek, M.J.; Kokkonen-Simon, K.M.; Chen, A.; Dunkerly-Eyring, B.L.; Vera, M.P.; Oeing, C.U.; Patel, C.H.; Nakamura, T.; Zhu, G.; Bedja, D.; et al. PKG1-modified TSC2 regulates mTORC1 activity to counter adverse cardiac stress. *Nature* 2019, **566**, 264–269. [CrossRef]

95. Seol, S.Y.; Lee, S.Y.; Kim, Y.D.; Do, E.J.; Kwon, J.A.; Kim, S.I.; Chu, I.S.; Leem, S.H. Minisatellite polymorphisms of the SLC6A19: Susceptibility in hypertension. *Biochem. Biophys. Res. Commun.* 2008, **374**, 714–719. [CrossRef]

96. Franchi-Gazzolla, R.; Visigalli, R.; Dall’Asta, V.; Sala, R.; Woo, S.K.; Kwon, H.M.; Gazzolla, G.C.; Bussolati, O. Amino acid depletion activates TonEBP and sodium-coupled inositol transport. *Am. J. Physiol. Cell Physiol.* 2001, **280**, C1465–C1474. [CrossRef] [PubMed]

97. Dmitrieva, N.I.; Burg, M.B. Secretion of von Willebrand factor by endothelial cells links sodium to hypercoagulability and thrombosis. *Proc. Natl. Acad. Sci. USA* 2014, **111**, 6485–6490. [CrossRef] [PubMed]

98. Madonna, R.; Giovannelli, G.; Confalone, P.; Renna, F.V.; Geng, Y.J.; De Caterina, R. High glucose-induced hyperosmolarity contributes to COX-2 expression and angiogenesis: Implications for diabetic retinopathy. *Cardiovasc. Diabetol.* 2016, **15**, 18. [CrossRef]

99. Li, W.; Moore, M.J.; Vasilieva, N.; Sui, J.; Wong, S.K.; Berne, M.A.; Somasundaran, M.; Sullivan, J.L.; Luzuriaga, K.; Greenough, T.C.; et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. *Nature* 2003, **426**, 450–454. [CrossRef]

100. Wu, K.; Li, W.; Peng, G.; Li, F. Crystal structure of NL63 respiratory coronavirus receptor-binding domain complexed with its human receptor. *Proc. Natl. Acad. Sci. USA* 2009, **106**, 19970–19974. [CrossRef] [PubMed]

101. Zhou, P.; Yang, X.L.; Wang, X.G.; Hu, B.; Zhang, L.; Zhang, W.; Si, H.R.; Zhu, Y.; Li, B.; Huang, C.L.; et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* 2020, **579**, 270–273. [CrossRef] [PubMed]

102. Hoffmann, M.; Klein-Weber, H.; Schroeder, S.; Kruger, N.; Herrler, T.; Erichsen, S.; Schiergens, T.S.; Herrler, G.; Wu, N.H.; Nitsche, A.; et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell* 2020, **180**, 271–280. [CrossRef]

103. Simmons, G.; Gosalia, D.N.; Rennekamp, A.J.; Reeves, J.D.; Diamond, S.L.; Bates, P. Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. *Proc. Natl. Acad. Sci. USA* 2005, **102**, 11876–11881. [CrossRef] [PubMed]

104. Brielle, E.S.; Schneidman-Duhovny, D.; Linial, M. The SARS-CoV-2 Exerts a Distinctive Strategy for Interacting with the ACE2 Human Receptor. *Viruses* 2020, **12**, 497. [CrossRef]

105. Coutard, B.; Valle, C.; de Lamballerie, X.; Canard, B.; Seidah, N.G.; Decroly, E. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. *Antiviral Res.* 2020, **176**, 104742. [CrossRef]

106. Bontempi, M.; Klein-Weber, H.; Pohlmann, S. A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells. *Mol. Cell* 2020, **78**, 779–784. [CrossRef]

107. Brielle, E.S.; Schneidman-Duhovny, D.; Linial, M. The SARS-CoV-2 Exerts a Distinctive Strategy for Interacting with the ACE2 Human Receptor. *Viruses* 2020, **12**, 497. [CrossRef]

108. Coutard, B.; Valle, C.; de Lamballerie, X.; Canard, B.; Seidah, N.G.; Decroly, E. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. *Antiviral Res.* 2020, **176**, 104742. [CrossRef]

109. Shang, J.; Wan, Y.; Luo, C.; Ye, G.; Geng, Q.; Auerbach, A.; Li, F. Cell entry mechanisms of SARS-CoV-2. *Proc. Natl. Acad. Sci. USA* 2020, **117**, 11727–11734. [CrossRef] [PubMed]

110. Kota, P.; Gentzsch, M.; Dang, Y.L.; Boucher, R.C.; Stutts, M.J. The N terminus of alpha-ENaC mediates ENaC cleavage and activation by furin. *J. Gen. Physiol.* 2018, **150**, 1179–1187. [CrossRef] [PubMed]

111. Liu, Y.; Yang, Y.; Zhang, C.; Huang, F.; Wang, F.; Yuan, J.; Wang, Z.; Li, J.; Li, J.; Feng, C.; et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. *Sci. China Life Sci.* 2020, **63**, 364–374. [CrossRef]

112. Guo, T.; Fan, Y.; Chen, M.; Wu, X.; Zhang, L.; He, T.; Wang, H.; Wan, J.; Wang, X.; Lu, Z. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). *JAMA Cardiol.* 2020, **5**, 848. [CrossRef] [PubMed]

113. Fosbol, E.L.; Butt, J.H.; Ostergaard, L.; Andersson, C.; Selmer, C.; Kraghholm, K.; Schou, M.; Phelps, M.; Gislason, G.H.; Gerds, T.A.; et al. Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality. *JAMA* 2020, **323**, 1769–1770. [CrossRef]

114. Jiang, R.D.; Liu, M.Q.; Chen, Y.; Shan, C.; Zhou, Y.W.; Shen, X.R.; Li, Q.; Zhang, L.; Zhu, Y.; Si, H.R.; et al. Pathogenesis of SARS-CoV-2 in Transgenic Mice Expressing Human Angiotensin-Converting Enzyme 2. *Cell* 2020, **182**, 50–58. [CrossRef]
113. Gualtieri, P.; Falcone, C.; Romano, L.; Macheda, S.; Correale, P.; Arciello, P.; Polimeni, N.; Lorenzo, A. Body Composition Findings by Computed Tomography in SARS-CoV-2 Patients: Increased Risk of Muscle Wasting in Obesity. *Int. J. Mol. Sci.* 2020, 21, 4670. [CrossRef] [PubMed]

114. Mao, R.; Qiu, Y.; He, J.S.; Tan, J.Y.; Li, X.H.; Liang, J.; Shen, J.; Zhu, L.R.; Chen, Y.; Iacucci, M.; et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: A systematic review and meta-analysis. *Lancet Gastroenterol. Hepatol.* 2020, 5, 667–678. [CrossRef]

115. Kiekens, C.; Boldrini, P.; Andreoli, A.; Avesani, R.; Gamma, F.; Grandi, M.; Lombardi, F.; Lusuardi, M.; Molteni, E.; Perboni, A.; et al. Rehabilitation and respiratory management in the acute and early post-acute phase. “Instant paper from the field” on rehabilitation answers to the Covid-19 emergency. *Eur. J. Phys. Rehabil. Med.* 2020, 56, 323–326. [CrossRef] [PubMed]

116. South, A.M.; Tomlinson, L.; Edmonston, D.; Hiremath, S.; Sparks, M.A. Controversies of renin-angiotensin system inhibition during the COVID-19 pandemic. *Nat. Rev. Nephrol.* 2020, 16, 305–307. [CrossRef]

117. Myti, D.; Gunjak, M.; Casado, F.; Khaghanı Raziabad, S.; Nardiello, C.; Vadasz, I.; Herold, S.; Pryhuber, G.; Seeger, W.; Morty, R.E. Elevated FiO2 increases SARS-CoV-2 co-receptor expression in respiratory tract epithelium. *Am. J. Physiol. Lung Cell. Mol. Physiol.* 2020, 319, L670–L674. [CrossRef]

118. Berman, J.M.; Awayda, R.G.; Awayda, M.S. Interacting domains in the epithelial sodium channel that mediate proteolytic activation. *Channels* 2015, 9, 281–290. [CrossRef]

119. Zhao, R.; Ali, G.; Nie, H.G.; Chang, Y.; Bhattarai, D.; Su, X.; Zhao, X.; Matthay, M.A.; Ji, H.L. Plasmin improves blood-gas barrier function in oedematous lungs by cleaving epithelial sodium channels. *Br. J. Pharmacol.* 2020, 177, 3091–3106. [CrossRef]

120. Vallé, V.; Chraibi, A.; Gaeggeler, H.P.; Horisberger, J.D.; Rossier, B.C. An epithelial serine protease activates the amiloride-sensitive sodium channel. *Nature* 1997, 389, 607–610. [CrossRef]

121. Chen, D.; Li, X.; Song, Q.; Hu, C.; Su, F.; Dai, J.; Ye, Y.; Huang, J.; Zhang, X.; Matthay, M.A.; Ji, H.L. Plasmin improves blood-gas barrier function in oedematous lungs by cleaving epithelial sodium channels. *Br. J. Pharmacol.* 2020, 177, 3091–3106. [CrossRef]

122. Lippi, G.; South, A.M.; Henry, B.M. Electrolyte imbalances in patients with severe coronavirus disease 2019 (COVID-19). *Ann. Clin. Biochem.* 2020, 57, 262–265. [CrossRef]

123. Oliveira, T.L.; Candeia-Medeiros, N.; Cavalcante-Araujo, P.M.; Melo, I.S.; Favaro-Pipi, E.; Fatima, L.A.; Rocha, A.A.; Goulart, L.R.; Machado, U.F.; Campos, R.R.; et al. SGLT1 activity in lung alveolar cells of diabetic rats modulates airway surface liquid glucose concentration and bacterial proliferation. *Sci. Rep.* 2016, 6, e21752. [CrossRef] [PubMed]

124. Palermo, N.E.; Sadhu, A.R.; McDonnell, M.E. Diabetic Ketoacidosis in COVID-19: Unique concerns and considerations. *J. Clin. Endocrinol. Metab.* 2020, 105, dgaa360. [CrossRef]

125. Kang, J.U.; Koo, S.H.; Kwon, K.C.; Park, J.W.; Kim, J.M. Gain at chromosomal region 5p15.33, containing TERT, is the most frequent genetic event in early stages of non-small cell lung cancer. *Cancer Genet. Cytogenet.* 2020, 182, 1–11. [CrossRef] [PubMed]

126. Zhang, L.; Yan, X.; Fan, Q.; Liu, H.; Liu, X.; Liu, Z.; Zhang, Z. D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. *J. Thromb. Haemost.* 2020, 18, 1324–1329. [CrossRef] [PubMed]

127. Chen, T.; Wu, D.; Chen, H.; Yan, W.; Yang, D.; Chen, G.; Ma, K.; Xu, D.; Yu, H.; Wang, H.; et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: Retrospective study. *BMJ* 2020, 368, m1091. [CrossRef]

128. Richardson, S.; Hirsch, J.S.; Narasimhan, M.; Crawford, J.M.; McGinn, T.; Davidson, K.W.; the Northwell, C.-R.C.; Barnaby, D.P.; Becker, L.B.; Chelico, J.D.; et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. *JAMA* 2020, 323, 2052–2059. [CrossRef] [PubMed]

129. Gavriliak, E.; Brodsky, R.A. Severe COVID-19 infection and thrombotic microangiopathy: Success does not come easily. *Br. J. Haematol.* 2020, 189, e227–e230. [CrossRef]

130. Nahum, J.; Morichau-Beauchant, T.; Daviaud, F.; Ecchegut, P.; Fichet, J.; Maillet, J.M.; Thierry, S. Venous Thrombosis Among Critically Ill Patients With Coronavirus Disease 2019 (COVID-19). *JAMA Netw. Open* 2020, 3, e2010478. [CrossRef]

131. Long, B.; Brady, W.J.; Koyfman, A.; Gottlieb, M. Cardiovascular complications in COVID-19. *Am. J. Emerg. Med.* 2020, 38, 1504–1507. [CrossRef]
133. Docherty, A.B.; Harrison, E.M.; Green, C.A.; Hardwick, H.E.; Pius, R.; Norman, L.; Holden, K.A.; Read, J.M.; Dondelinger, F.; Carson, G.; et al. Features of 20 133 UK patients in hospital with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol: Prospective observational cohort study. *BMJ* 2020, 369, m1985. [CrossRef]

134. Ding, Y.; Wang, H.; Shen, H.; Li, Z.; Geng, J.; Han, H.; Cai, J.; Li, X.; Kang, W.; Weng, D.; et al. The clinical pathology of severe acute respiratory syndrome (SARS): A report from China. *J. Pathol.* 2003, 200, 282–289. [CrossRef]

135. Chen, J.; Jiang, Q.; Xia, X.; Liu, K.; Yu, Z.; Tao, W.; Gong, W.; Han, J.J. Individual variation of the SARS-CoV-2 receptor ACE2 gene expression and regulation. *Aging Cell* 2020, 19, e13168. [CrossRef]

136. Mogi, M. Effect of renin-angiotensin system on senescence. *Geriatr. Gerontol. Int.* 2020, 20, 520–525. [CrossRef]

137. Ellinghaus, K. The ABO blood group locus and a chromosome 3 gene cluster associate with SARS-CoV-2 respiratory failure in an Italian-Spanish genome-wide association analysis. *medRxiv* 2020. [CrossRef]

138. Bigiani, A. Does ENaC Work as Sodium Taste Receptor in Humans? *Nutrients* 2020, 12, 1195. [CrossRef]

139. Shigemura, N.; Ohkuri, T.; Sadamitsu, C.; Yasumatsu, K.; Yoshida, R.; Beauchamp, G.K.; Bachmanov, A.A.; Ninomiya, Y. Amiloride-sensitive NaCl taste responses are associated with genetic variation of ENaC alpha-subunit in mice. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* 2008, 294, R66–R75. [CrossRef]

140. Eylam, S.; Spector, A.C. Oral amiloride treatment decreases taste sensitivity to sodium salts in C57BL/6 and DBA/2 mice. *Chem. Sens. Senses* 2003, 28, 447–458. [CrossRef] [PubMed]

141. Yamamura, H.; Ugawa, S.; Ueda, T.; Nagao, M.; Joh, T.; Shimada, S. Epithelial Na+ channel delta subunit is an acid sensor in the human oesophagus. *Eur. J. Pharmacol.* 2008, 600, 32–36. [CrossRef] [PubMed]

142. Nomura, K.; Nakanishi, M.; Ishidate, F.; Iwata, K.; Taruno, A. All-Electrical Ca(2+) Independent Signal Transduction Mediates Attractive Sodium Taste in Taste Buds. *Neuron* 2020, 106, 816–829. [CrossRef]

143. Chandrashekar, J.; Kuhn, C.; Oka, Y.; Yarmolinsky, D.A.; Hummler, E.; Ryba, N.J.; Zuker, C.S. The cells and peripheral representation of sodium taste in mice. *Nature* 2010, 464, 297–301. [CrossRef] [PubMed]

144. Shigemura, N.; Iwata, S.; Yasumatsu, K.; Ohkuri, T.; Horio, N.; Sanematsu, K.; Yoshida, R.; Margolskee, R.F.; Ninomiya, Y. Angiotensin II modulates salty and sweet taste sensitivities. *J. Neurosci.* 2013, 33, 6267–6277. [CrossRef] [PubMed]

145. Kumarhia, D.; He, L.; McCluskey, L.P. Inflammatory stimuli acutely modulate peripheral taste function. *J. Neurophysiol.* 2016, 115, 2964–2975. [CrossRef]

146. Bangel, N.; Dahlhoff, C.; Sobczak, K.; Weber, W.M.; Kusche-Vihrog, K. Upregulated expression of ENaC in human CF nasal epithelium. *J. Cyst Fibr.* 2008, 7, 197–205. [CrossRef]

147. Bilinska, K.; Jakubowska, P.; Von Bartheld, C.S.; Butowt, R. Expression of the SARS-CoV-2 Entry Proteins, ACE2 and TMPRSS2, in Cells of the Olfactory Epithelium: Identification of Cell Types and Trends with Age. *ACS Chem. Neurosci.* 2020, 11, 1555–1562. [CrossRef] [PubMed]

148. Ng, R.; Salem, S.S.; Wu, S.T.; Wu, M.; Lin, H.H.; Shepherd, A.K.; Joiner, W.J.; Wang, J.W.; Su, C.Y. Amplification of Drosophila Olfactory Responses by a DEG/ENaC Channel. *Neuron* 2019, 104, 947–950. [CrossRef]

149. Chodroff, L.; Bendele, M.; Valenzuela, V.; Henry, M.; Ruparel, S. EXPRESS: BDNF Signaling Contributes to Oral Cancer Pain in a Preclinical Orthotopic Rodent Model. *Mol. Pain* 2016, 12. [CrossRef]

150. Xu, H.; Zhong, L.; Deng, J.; Peng, J.; Dan, H.; Zeng, X.; Li, T.; Chen, Q. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. *Int. J. Oral Sci.* 2020, 12, 8. [CrossRef]

151. Yamamura, H.; Ugawa, S.; Ueda, T.; Nagao, M.; Shimada, S. Protons activate the delta-subunit of the epithelial Na+ channel in humans. *J. Biol. Chem.* 2004, 279, 12529–12534. [CrossRef]

152. Yamamura, H.; Ugawa, S.; Ueda, T.; Nagao, M.; Shimada, S. Epithelial Na+ channel delta subunit mediates acid-induced ATP release in the human skin. *Biochem. Biophys. Res. Commun.* 2008, 373, 155–158. [CrossRef]

153. Ji, H.L.; Benos, D.J. Degenerin sites mediate proton activation of deltabetagamma-epithelial sodium channel. *J. Biol. Chem.* 2004, 279, 26939–26947. [CrossRef] [PubMed]

154. Orr, B.O.; Gorczycza, D.; Younger, M.A.; Jan, L.Y.; Jan, Y.N.; Davis, G.W. Composition and Control of a DEG/ENaC Channel during Presynaptic Homeostatic Plasticity. *Cell Rep.* 2017, 20, 1855–1866. [CrossRef] [PubMed]
155. Tasker, J.G.; Prager-Khoutorsky, M.; Teruyama, R.; Lemos, J.R.; Amstrong, W.E. Advances in the neurophysiology of magnocellular neuroendocrine cells. *J. Neuroendocrinol.* 2020, 32, e12826. [CrossRef] [PubMed]

156. Lang, F.; Artunc, F.; Vallon, V. The physiological impact of the serum and glucocorticoid-inducible kinase SGK1. *Curr. Opin. Nephrol. Hypertens.* 2009, 18, 439–448. [CrossRef]

157. Wesci, D.; Miranda, P.; Afonso-Oramas, D.; Althaus, M.; Castro-Hernandez, J.; Dominguez, J.; Morty, R.E.; Clauss, W.; Gonzalez-Hernandez, T.; Alvarez de la Rosa, D.; et al. The neuronal-specific SGK1.1 kinase regulates [delta]-epithelial Na+ channel independently of PY motifs and couples it to phospholipase C signaling. *Am. J. Physiol. Cell Physiol.* 2010, 299, C779–C790. [CrossRef]

158. Mills, N.J.; Sharma, K.; Haque, M.; Moore, M.; Teruyama, R. Aldosterone Mediated Regulation of Epithelial Sodium Channel (ENaC) Subunits in the Rat Hypothalamus. *Neuroscience* 2018, 390, 278–292. [CrossRef]

159. Yanpallewar, S.; Wang, T.; Koh, D.C.; Quarta, E.; Fulgenzi, G.; Tessarollo, L. Nedd4-2 haploinsufficiency causes hyperactivity and increased sensitivity to inflammatory stimuli. *Sci. Rep.* 2016, 6, 32957. [CrossRef]

160. Garcia-Caballero, A.; Gandini, M.A.; Huang, S.; Chen, L.; Souza, I.A.; Dang, Y.L.; Stutts, M.J.; Zamponi, G.W. Cav3.2 calcium channel interactions with the epithelial sodium channel ENaC. *Brain* 2019, 12, 12. [CrossRef]

161. The Human Protein Atlas. Available online: https://www.proteinatlas.org/search/ENaC (accessed on 17 August 2020).

162. Lam, D.K.; Dang, D.; Flynn, A.N.; Hardt, M.; Schmidt, B.L. TMPRRSS2, a novel membrane-anchored mediator in cancer pain. *Pain* 2015, 156, 923–930. [CrossRef]

163. Kehoe, P.G.; Wong, S.; Al Mulhim, N.; Palmer, L.E.; Miners, J.S. Angiotensin-converting enzyme 2 is reduced in Alzheimer’s disease in association with increasing amyloid-beta and tau pathology. *Alzheimers Res. Ther.* 2016, 8, 50. [CrossRef]

164. Krause, E.G.; de Kloet, A.D.; Scott, K.A.; Flak, J.N.; Jones, K.; Smeltzer, M.D.; Ulrich-Lai, Y.M.; Woods, S.C.; Wilson, S.P.; Reagan, L.P.; et al. Blood-borne angiotensin II acts in the brain to influence behavioral and endocrine responses to psychogenic stress. *J. Neurosci.* 2011, 31, 15009–15015. [CrossRef] [PubMed]

165. Wang, L.; de Kloet, A.D.; Pati, D.; Hiller, H.; Smith, J.A.; Pioquinto, D.J.; Ludin, J.A.; Oh, S.P.; Katovich, M.J.; Frazier, C.J.; et al. Increasing brain angiotensin converting enzyme 2 activity decreases anxiety-like behavior in male mice by activating central Mas receptors. *Neuropharmacology* 2016, 105, 114–123. [CrossRef] [PubMed]

166. Wang, L.A.; de Kloet, A.D.; Smeltzer, M.D.; Cahill, K.M.; Hiller, H.; Bruce, E.B.; Pioquinto, D.J.; Ludin, J.A.; Katovich, M.J.; Raizada, M.K.; et al. Coupling corticotropin-releasing-hormone and angiotensin converting enzyme 2 dampens stress responsiveness in male mice. *Neuropharmacology* 2018, 133, 85–93. [CrossRef]

167. de Kloet, A.D.; Cahill, K.M.; Scott, K.A.; Krause, E.G. Overexpression of angiotensin converting enzyme 2 reduces anxiety-like behavior in female mice. *Physiol. Behav.* 2020, 224, 113002. [CrossRef]

168. Gu, J.; Gong, E.; Zhang, B.; Zheng, J.; Gao, Z.; Zhong, Y.; Zou, W.; Zhan, J.; Wang, S.; Xie, Z.; et al. Multiple organ infection and the pathogenesis of SARS. *J. Exp. Med.* 2005, 202, 415–424. [CrossRef]

169. Song, L. Neuroinvasive potential of SARS-CoV-2 revealed in a human brain organoid model. *BioRxiv* 2020. [CrossRef]

170. Song, E.; Zhang, C.; Israelow, B.; Lu-Culligan, A.; Prado, A.V.; Skriabine, S.; Lu, P.; Weizman, O.-E.; Liu, F.; Dai, Y.; et al. Neuroinvasion of SARS-CoV-2 in human and mouse brain. *BioRxiv* 2020. [CrossRef]

171. Cantuti-Castelvetri, L.; Ohja, R.; Pedro, L.D.; Djannatian, M.; Franz, J.; Kuivanen, S.; van der Meer, F.; Kallio, K.; Kaya, T.; Anastasia, M.; et al. Neurupolin-1 facilitates SARS-CoV-2 cell entry and infectivity. *Science* 2020. [CrossRef]

172. Fotuhi, M.; Mian, A.; Meysami, S.; Raji, C.A. Neurobiology of COVID-19. *J. Alzheimers Dis.* 2020, 76, 3–19. [CrossRef] [PubMed]

173. Brouwer, M.C.; Ascione, T.; Pagliano, P. Neurologic aspects of covid-19: A concise review. *Infez. Med.* 2020, 28, 42–45. [CrossRef]

174. Sheraton, M.; Deo, N.; Kashyap, R.; Surani, S. A Review of Neurological Complications of COVID-19. *Cureus* 2020, 12, e8192. [CrossRef]

175. Helms, J.; Kremer, S.; Merdji, H.; Clerc-Jehl, R.; Schenck, M.; Kummerlen, C.; Collange, O.; Boulay, C.; Fafi-Kremer, S.; Ohana, M.; et al. Neurologic Features in Severe SARS-CoV-2 Infection. *N. Engl. J. Med.* 2020, 382, 2268–2270. [CrossRef]
176. Lechien, J.R.; Chiesa-Estomba, C.M.; De Siati, D.R.; Horoi, M.; Le Bon, S.D.; Rodriguez, A.; Dequanter, D.; Bleic, S.; El Afia, F; Distinguin, L.; et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): A multicenter European study. *Eur. Arch. Otorhinolaryngol*. 2020, 277, 2251–2261. [CrossRef] [PubMed]

177. Xu, J.; Srimamu, S.; Xia, H.; Moreno-Walton, L.; Culicchia, F.; Domenig, O.; Poglitsch, M.; Lazartigues, E. Clinical Relevance and Role of Neuronal AT1 Receptors in ADAM17-Mediated ACE2 Shedding in Neurogenic Hypertension. *Circ. Res*. 2017, 121, 43–55. [CrossRef]

178. Giacomelli, A.; Pezzati, L.; Conti, F.; Bernacchia, D.; Siano, M.; Oreni, L.; Rusconi, S.; Gervasoni, C.; Ridolfo, A.L.; Rizzardini, G.; et al. Self-reported olfactory and taste disorders in SARS-CoV-2 patients: A cross-sectional study. *Clin. Infect. Dis.* 2020, 71, 889–890. [CrossRef]

179. Meng, X.; Deng, Y.; Dai, Z.; Meng, Z. COVID-19 and anosmia: A review based on up-to-date knowledge. *Am. J. Otolaryngol*. 2020, 41, 102581. [CrossRef] [PubMed]

180. Epstein, D.; Andrawis, W.; Lipsky, A.M.; Ziad, H.A.; Matan, M. Anxiety and Suicidality in a Hospitalized Patient with COVID-19 Infection. *Eur. J. Case Rep. Intern. Med.* 2020, 7, 001651. [CrossRef] [PubMed]

181. Bouhaddou, M.; Memon, D.; Meyer, B.; White, K.M.; Rezelj, V.V.; Marrero, M.C.; Polacco, B.J.; Melnyk, J.E.; Altmayer, S.; Zanon, M.; Pacini, G.S.; Watte, G.; Barros, M.C.; Mohammed, T.L.; Verma, N.; Marchiori, E.; Hochhegger, B. Comparison of the computed tomography findings in COVID-19 and other viral pneumonia in immunocompetent adults: A systematic review and meta-analysis. *Eur. Radiol*. 2020, 30, 1–12.

182. Lu, Y.; Liu, D.X.; Tam, J.P. Lipid rafts are involved in SARS-CoV entry into Vero E6 cells. *Biochem. Biophys. Res. Commun.* 2008, 369, 344–349. [CrossRef]

183. Lu, Y.; Liu, D.X.; Tam, J.P. Lipid rafts are involved in SARS-CoV entry into Vero E6 cells. *Biochem. Biophys. Res. Commun.* 2008, 369, 344–349. [CrossRef] [PubMed]

184. Tellier, E.; Canault, M.; Rebsomen, L.; Bonardo, B.; Juhan-Vague, I.; Nalbone, G.; Peiretti, F. The shedding activity of ADAM17 is sequestered in lipid rafts. *Exp. Cell Res.* 2006, 312, 3969–3980. [CrossRef] [PubMed]

185. Veit, G.; Zimina, E.P.; Franzke, C.W.; Kutsch, S.; Siebolds, U.; Gordon, M.K.; Bruckner-Tuderman, L.; Koch, M. Shedding of collagen XXIII is mediated by furin and depends on the plasma membrane microenvironment. *J. Biol. Chem.* 2007, 282, 27424–27435. [CrossRef] [PubMed]

186. Tellier, E.; Canault, M.; Poggi, M.; Bonardo, B.; Nicolay, A.; Alessi, M.C.; Naillon, G.; Peiretti, F. HDLs activate ADAM17-dependent shedding. *J. Cell. Physiol.* 2008, 214, 687–693. [CrossRef] [PubMed]

187. Bifulco, M.; Gazzerro, P. Statin therapy in COVID-19 infection: Much more than a single pathway. *Cell Metab.* 2020, 32, 176–187. [CrossRef]

188. Subir, R.; Jagat, J.M.; Kalyan, K.G. Pros and cons for use of statins in people with coronavirus disease-19 (COVID-19). *Diabetes Metab. Syndr.* 2020, 14, 1225–1229. [CrossRef] [PubMed]

189. Zhang, X.J.; Qin, J.J.; Cheng, X.; Shen, L.; Zhao, Y.C.; Yuan, Y.; Lei, F.; Chen, M.M.; Yang, H.; Bai, L.; et al. In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19. *Cell Metab.* 2020, 32, 176–187. [CrossRef]

190. Rodriguez-Nava, G.; Trelles-Garcia, D.P.; Yanez-Bello, M.A.; Chung, C.W.; Trelles-Garcia, V.P.; Friedman, H.J. Atorvastatin associated with decreased hazard for death in COVID-19 patients admitted to an ICU: A retrospective cohort study. *Crit. Care* 2020, 24, 429. [CrossRef]

191. Aggarwal, N.K.; Subramanian, A. Antifibrinolitics and cardiac surgery: The past, the present, and the future. *Ann. Card Anaesth.* 2020, 23, 193–199.

192. Solun, B.; Shoenfeld, Y. Inhibition of metalloproteinases in therapy for severe lung injury due to COVID-19. *Med. Drug Discov.* 2020, 7, 100052. [CrossRef]

193. Kim, T.S.; Heinlein, C.; Hackman, R.C.; Nelson, P.S. Phenotypic analysis of mice lacking the Tmprss2-encoded protease. *Mol. Cell. Biol.* 2006, 26, 965–975. [CrossRef]

194. Kim, T.S.; Heinlein, C.; Hackman, R.C.; Nelson, P.S. Phenotypic analysis of mice lacking the Tmprss2-encoded protease. *Mol. Cell. Biol.* 2006, 26, 965–975. [CrossRef]

195. Wilson, L.; McKinlay, C.; Gage, P.; Ewart, G. SARS coronavirus E protein forms cation-selective ion channels. *Virology* 2004, 330, 322–331. [CrossRef] [PubMed]
196. Rodriguez-Morales, A.J.; Cardona-Ospina, J.A.; Gutierrez-Ocampo, E.; Villamizar-Pena, R.; Holguin-Rivera, Y.; Escalera-Antezana, J.P.; Alvarado-Arnez, L.E.; Bonilla-Aldana, D.K.; Franco-Paredes, C.; Henao-Martinez, A.F.; et al. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. *Travel. Med. Infect. Dis.* 2020, 34, 101623. [CrossRef] [PubMed]

197. Klok, F.A.; Kruip, M.; van der Meer, N.J.M.; Arbous, M.S.; Gommers, D.; Kant, K.M.; Kaptein, F.H.J.; van Paassen, J.; Stals, M.A.M.; Huisman, M.V.; et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. *Thromb. Res.* 2020, 191, 145–147. [CrossRef]

198. Wei, W.E.; Li, Z.; Chiew, C.J.; Yong, S.E.; Toh, M.P.; Lee, V.J. Presymptomatic Transmission of SARS-CoV-2 - Singapore, January 23-March 16 2020. *MMWR Morb. Mortal. Wkly. Rep.* 2020, 69, 411–415. [CrossRef] [PubMed]

199. Beigel, J.H.; Tomashek, K.M.; Dodd, L.E.; Mehta, A.K.; Zingman, B.S.; Kalil, A.C.; Hohmann, E.; Chu, H.Y.; Luetkemeyer, A.; Kline, S.; et al. Remdesivir for the Treatment of Covid-19 - Preliminary Report. *N. Engl. J. Med.* 2020. [CrossRef]

200. Lei, C.; Qian, K.; Li, T.; Zhang, S.; Fu, W.; Ding, M.; Hu, S. Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig. *Nat. Commun.* 2020, 11, 2070. [CrossRef] [PubMed]

201. Libby, P.; Luscher, T. COVID-19 is, in the end, an endothelial disease. *Eur. Heart J.* 2020, 41, 3038–3044. [CrossRef] [PubMed]

202. Lowenstein, C.J.; Solomon, S.D. Severe COVID-19 is a Microvascular Disease. *Circulation* 2020, 395, 1417–1418. [CrossRef]

203. Scala, I.; Riccio, M.P.; Marino, M.; Bravaccio, C.; Parenti, G.; Strisciuglio, P. Large Neutral Amino Acids (LNAA)s Supplementation Improves Neuropsychological Performances in Adult Patients with Phenylketonuria. *Nutrients* 2020, 12, 1092. [CrossRef]

204. Saeedi Saravi, S.S.; Beer, J.H. Apelin-potential therapy for COVID-19? *J. Mol. Cell. Cardiol.* 2020, 145, 84–87. [CrossRef] [PubMed]

**Publisher’s Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).